U.S. patent application number 13/727632 was filed with the patent office on 2013-07-11 for human lysosomal proteins from plant cell culture.
This patent application is currently assigned to Protalix Ltd.. The applicant listed for this patent is Protalix Ltd.. Invention is credited to Daniel Bartfeld, Gideon Baum, Sharon Hashmueli, Ayala Lewkowicz, Yoseph SHAALTIEL.
Application Number | 20130177538 13/727632 |
Document ID | / |
Family ID | 39929901 |
Filed Date | 2013-07-11 |
United States Patent
Application |
20130177538 |
Kind Code |
A1 |
SHAALTIEL; Yoseph ; et
al. |
July 11, 2013 |
HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE
Abstract
A device, system and method for producing glycosylated proteins
in plant culture, particularly proteins having a high mannose
glycosylation, while targeting such proteins with an ER signal
and/or by-passing the Golgi. The invention further relates to
vectors and methods for expression and production of enzymatically
active high mannose lysosomal enzymes using transgenic plant root,
particularly carrot cells. More particularly, the invention relates
to host cells, particularly transgenic suspended carrot cells,
vectors and methods for high yield expression and production of
biologically active high mannose Glucocerebrosidase (GCD). The
invention further provides for compositions and methods for the
treatment of lysosomal storage diseases.
Inventors: |
SHAALTIEL; Yoseph; (Kibbutz
HaSolelim, IL) ; Baum; Gideon; (Kibbutz Ayelet
HaShachar, IL) ; Bartfeld; Daniel; (Moran, IL)
; Hashmueli; Sharon; (Ramot-Naftali, IL) ;
Lewkowicz; Ayala; (Kfar-Vradim, IL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Protalix Ltd.; |
Carmiel |
|
IL |
|
|
Assignee: |
Protalix Ltd.
Carmiel
IL
|
Family ID: |
39929901 |
Appl. No.: |
13/727632 |
Filed: |
December 27, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13080694 |
Apr 6, 2011 |
8449876 |
|
|
13727632 |
|
|
|
|
11790991 |
Apr 30, 2007 |
7951557 |
|
|
13080694 |
|
|
|
|
10554387 |
Oct 25, 2005 |
|
|
|
PCT/IL2004/000181 |
Feb 24, 2004 |
|
|
|
11790991 |
|
|
|
|
Current U.S.
Class: |
424/93.21 ;
435/419 |
Current CPC
Class: |
A61P 7/06 20180101; C12Y
302/01022 20130101; A61P 19/00 20180101; C12N 9/2405 20130101; A61P
1/16 20180101; A61P 7/00 20180101; C12N 9/2434 20130101; C12Y
302/01045 20130101; A61P 11/00 20180101; A61K 9/0053 20130101; C07K
2319/04 20130101; A61K 36/23 20130101; C12P 21/005 20130101; A61P
43/00 20180101; A61K 38/47 20130101; C12N 9/2465 20130101; C12N
15/8257 20130101; A61P 19/08 20180101; A61P 7/04 20180101; A61P
7/02 20180101 |
Class at
Publication: |
424/93.21 ;
435/419 |
International
Class: |
A61K 36/23 20060101
A61K036/23 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 27, 2003 |
IL |
155588 |
Claims
1. A pharmaceutical composition for treatment or prevention of a
disease associated with a deficiency in a lysosomal enzyme function
comprising lyophilized plant cells comprising a recombinant
lysosomal enzyme protein and a pharmaceutically acceptable
carrier.
2. The pharmaceutical composition of claim 1, wherein said
recombinant lysosomal enzyme is selected from the group consisting
of alpha galactosidase, ceramidase, beta galactosidase, beta
hexosaminidase, sphingomyelinase, alpha-N-acetylgalactosaminidase,
iduronate-2-sulfatase, beta-glucoronidase, iduronidase and
mannose-6-phosphate transporter.
3. The pharmaceutical composition of claim 1, wherein said
recombinant human lysosomal enzyme is glycosylated.
4. The pharmaceutical composition of claim 1, wherein said plant
cell is a carrot cell.
5. The pharmaceutical composition of claim 4, wherein said plant
cell is a carrot cell from suspension culture.
6. The pharmaceutical composition of claim 1 formulated for oral
administration.
7. The pharmaceutical composition of claim 1, wherein said
recombinant human lysosomal enzyme has lysosomal enzyme biological
activity.
8. A composition of matter comprising lyophilized plant cells
comprising a recombinant human lysosomal enzyme protein.
9. The composition of matter of claim 8, wherein said human
lysosomal enzyme protein is selected from the group consisting of
alpha galactosidase, ceramidase, beta galactosidase, beta
hexosaminidase, sphingomyelinase, alpha-N-acetylgalactosaminidase,
iduronate-2-sulfatase, beta-glucoronidase, iduronidase and
mannose-6-phosphate transporter.
10. The composition of matter of claim 8, wherein said plant cell
is a carrot cell.
11. The composition of matter of claim 8, wherein said plant cell
is a carrot cell from suspension culture.
12. The composition of matter of claim 8 formulated for oral
administration.
13. The composition of matter of claim 8, wherein said recombinant
human lysosomal enzyme protein has lysosomal enzyme catalytic
activity.
14. A method of treating or preventing a disease associated with a
deficiency in a lysosomal enzyme function in a subject comprising
orally administering lyophilized plant cells comprising a
recombinant lysosomal enzyme protein.
15. The method of claim 14, wherein said disease is selected from
the group consisting of Fabry disease, Farber disease, G.sub.ml
gangliosidosis, Tay-Sachs disease, Niemann-Pick disease, Schindler
disease, Hunter syndrome, Sly syndrome, Hurler and Hurler/Scheie
syndromes, and I-Cell/San Filipo syndrome.
16. The method of claim 14, wherein said disease is Fabry disease
and said recombinant lysosomal enzyme protein is
alpha-galactosidase.
17. The method of claim 14, wherein said disease is Farber disease
and said recombinant lysosomal enzyme protein is ceramidase.
18. The method of claim 14, wherein said disease is G.sub.ml
gangliosidosis and said recombinant lysosomal enzyme protein is
beta-galactosidase.
19. The method of claim 14, wherein said disease is Tay-Sachs
disease and said recombinant lysosomal enzyme protein is
beta-hexosaminidase.
20. The method of claim 14, wherein said disease is Niemann-Pick
disease and said recombinant lysosomal enzyme protein is
sphingomyelinase.
21. The method of claim 14, wherein said disease is Schindler
disease and said recombinant lysosomal enzyme protein is
alpha.-N-acetylgalactosaminidase.
22. The method of claim 14, wherein said disease is Hunter syndrome
and said recombinant lysosomal enzyme protein is
iduronate-2-sulfatase.
23. The method of claim 14, wherein said disease is Sly syndrome
and said recombinant lysosomal enzyme protein is
beta-glucuronidase.
24. The method of claim 14, wherein said disease is Hurler or
Hurler/Scheie syndrome and said recombinant lysosomal enzyme
protein is iduronidase.
25. The method of claim 14, wherein said disease is I-Cell/San
Filipo syndrome and said recombinant lysosomal enzyme protein is
mannose 6-phosphate transporter.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 13/080,694 filed on Apr. 6, 2011, which is a
division of U.S. patent application Ser. No. 11/790,991 filed on
Apr. 30, 2007, now U.S. Pat. No. 7,951,557, which is a
continuation-in-part (CIP) of U.S. patent application Ser. No.
10/554,387 filed on Oct. 25, 2005, now abandoned, which is a
National Phase of PCT Patent Application No. PCT/IL2004/000181
filed on Feb. 24, 2004, which claims the benefit of priority of
Israel Patent Application No. 155588 filed Apr. 27, 2003, now
abandoned. The contents of the above applications are all
incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to transformed host cells for
the production of high mannose proteins and a method and system for
producing these proteins, particularly in plant culture.
BACKGROUND OF THE INVENTION
[0003] Gaucher's disease is the most prevalent lysosomal storage
disorder. It is caused by a recessive genetic disorder (chromosome
1 q21-q31) resulting in deficiency of glucocerebrosidase, also
known as glucosylceramidase, which is a membrane-bound lysosomal
enzyme that catalyzes the hydrolysis of the glycosphingolipid
glucocerebroside (glucosylceramide, GlcCer) to glucose and
ceramide. Gaucher disease is caused by point mutations in the hGCD
(human glucocerebrosidase) gene (GBA), which result in accumulation
of GlcCer in the lysosomes of macrophages. The characteristic
storage cells, called Gaucher cells, are found in liver, spleen and
bone marrow. The associated clinical symptoms include severe
hepatosplenomegaly, anemia, thrombocytopenia and skeletal
deterioration.
[0004] The gene encoding human GCD was first sequenced in 1985 (6)
The protein consists of 497 amino acids derived from a 536-mer
pro-peptide. The mature hGCD contains five N-glycosylation amino
acid consensus sequences (Asn-X-Ser/Thr). Four of these sites are
normally glycosylated. Glycosylation of the first site is essential
for the production of active protein. Both high-mannose and complex
oligosaccharide chains have been identified (7). hGCD from placenta
contains 7% carbohydrate, 20% of which is of the high-mannose type
(8). Biochemical and site-directed mutagenesis studies have
provided an initial map of regions and residues important to
folding, activator interaction, and active site location (9).
[0005] Treatment of placental hGCD with neuraminidase (yielding an
asialo enzyme) results in increased clearance and uptake rates by
rat liver cells with a concomitant increase in hepatic enzymatic
activity (Furbish et al., 1981, Biochim Biophys. Acta 673:425-434).
This glycan-modified placental hGC is currently used as a
therapeutic agent in the treatment of Gaucher's disease.
Biochemical and site-directed mutagenesis studies have provided an
initial map of regions and residues important to folding, activator
interaction, and active site location [Grace et al., J. Biol. Chem.
269:2283-2291 (1994)].
[0006] There are three different types of Gaucher disease, each
determined by the level of hGC activity. The major cells affected
by the disease are the macrophages, which are highly enlarged due
to GlcCer accumulation, and are thus referred to as "Gaucher
cells".
[0007] The identification of a defect in GCD as the primary cause
of Gaucher's disease led to the development of enzyme replacement
therapy as a therapeutic strategy for this disorder.
[0008] De Duve first suggested that replacement of the missing
lysosomal enzyme with exogenous biologically active enzyme might be
a viable approach to treatment of lysosomal storage diseases [Fed
Proc. 23:1045 (1964)].
[0009] Since that time, various studies have suggested that enzyme
replacement therapy may be beneficial for treating various
lysosomal storage diseases. The best success has been shown with
individuals with type I Gaucher disease, who were treated with
exogenous enzyme (.beta.-glucocerebrosidase), prepared from
placenta (Ceredase.TM.) or, more recently, recombinantly
(Cerezyme.TM.).
[0010] Unmodified glucocerebrosidase derived from natural sources
is a glycoprotein with four carbohydrate chains. This protein does
not target the phagocytic cells in the body and is therefore of
limited therapeutic value. In developing the current therapy for
Gaucher's disease, the terminal sugars on the carbohydrate chains
of glucocerebrosidase are sequentially removed by treatment with
three different glycosidases. This glycosidase treatment results in
a glycoprotein whose terminal sugars consist of mannose residues.
Since phagocytes have mannose receptors that recognize
glycoproteins and glycopeptides with oligosaccharide chains that
terminate in mannose residues, the carbohydrate remodeling of
glucocerebrosidase has improved the targeting of the enzyme to
these cells [Furbish et al., Biochem. Biophys. Acta 673:425,
(1981)].
[0011] As indicated herein, glycosylation plays a crucial role in
hGCD activity, therefore deglycosylation of hGCD expressed in cell
lines using either tunicamycin (Sf9 cells) or point mutations
abolishing all glycosylation sites (both Sf9 and COS-1 cells),
results in complete loss of enzymatic activity. In addition, hGCD
expressed in E. coli was found to be inactive. Further research
indicated the significance of the various glycosylation sites for
protein activity. In addition to the role of glycosylation in the
actual protein activity, the commercially produced enzyme contains
glycan sequence modifications that facilitate specific drug
delivery. The glycosylated proteins are remodeled following
extraction to include only mannose containing glycan sequences.
[0012] The human GCD enzyme contains 4 glycosylation sites and 22
lysines. The recombinantly produced enzyme (Cerezyme.TM.) differs
from the placental enzyme (Ceredase.TM.) in position 495 where an
arginine has been substituted with a histidine. Furthermore, the
oligosaccharide composition differs between the recombinant and the
placental GCD as the former has more fucose and
N-acetyl-glucosamine residues while the latter retains one high
mannose chain. As mentioned above, both types of GCDs are treated
with three different glycosidases (neuraminidase, galactosidase,
and P-N acetyl-glucosaminidase) to expose terminal mannoses, which
enables targeting of phagocytic cells. A pharmaceutical preparation
comprising the recombinantly produced enzyme is described in U.S.
Pat. No. 5,549,892. It should be noted that all references
mentioned are hereby incorporated by reference as if fully set
forth herein.
[0013] One drawback associated with existing lysosomal enzyme
replacement therapy treatment is that the in vivo bioactivity of
the enzyme is undesirably low, e.g. because of low uptake, reduced
targeting to lysosomes of the specific cells where the substrate is
accumulated, and a short functional in vivo half-life in the
lysosomes.
[0014] Another major drawback of the existing GCD recombinant
enzymes is their expense, which can place a heavy economic burden
on health care systems. The high cost of these recombinant enzymes
results from a complex purification protocol, and the relatively
large amounts of the therapeutic required for existing treatments.
There is therefore, an urgent need to reduce the cost of GCD so
that this life saving therapy can be provided to all who require it
more affordably.
[0015] Proteins for pharmaceutical use have been traditionally
produced in mammalian or bacterial expression systems. In the past
decade a new expression system has been developed in plants. This
methodology utilizes Agrobacterium, a bacteria capable of inserting
single stranded DNA molecules (T-DNA) into the plant genome. Due to
the relative simplicity of introducing genes for mass production of
proteins and peptides, this methodology is becoming increasingly
popular as an alternative protein expression system (1).
[0016] While post translational modifications do not exist in
bacterial expression systems, plant derived expression systems do
facilitate these modifications known to be crucial for protein
expression and activity. One of the major differences between
mammalian and plant protein expression system is the variation of
protein sugar side chains, caused by the differences in
biosynthetic pathways. Glycosylation was shown to have a profound
effect on activity, folding, stability, solubility, susceptibility
to proteases, blood clearance rate and antigenic potential of
proteins. Hence, any protein production in plants should take into
consideration the potential ramifications of plant
glycosylation.
[0017] Protein glycosylation is divided into two categories:
N-linked and O-linked modifications (2). The two types differ in
amino acid to which the glycan moiety is attached to --N-linked are
attached to Asn residues, while O-linked are attached to Ser or Thr
residues. In addition, the glycan sequences of each type bears
unique distinguishing features. Of the two types, N-linked
glycosylation is the more abundant, and its effect on protein
function has been extensively studied. O-linked glycans, on the
other hand are relatively scarce, and less information is available
regarding their affect on proteins.
SUMMARY OF THE INVENTION
[0018] The background art does not teach or suggest a device,
system or method for selectively producing glycosylated proteins in
plant culture. The background art also does not teach or suggest
such a device, system or method for producing high mannose proteins
in plant culture. The background art also does not teach or suggest
a device, system or method for producing proteins in plant culture
through the endoplasmic reticulum (ER). The background art also
does not teach or suggest such a device, system or method for
producing proteins in plant culture through the endoplasmic
reticulum (ER) while by-passing the Golgi body. The background art
also does not teach or suggest such a device, system or method for
producing proteins in plant culture by using an ER signal to
by-pass the Golgi body.
[0019] The present invention overcomes these disadvantages of the
background art by providing a device, system and method for
producing glycosylated proteins in plant culture, particularly
proteins having a high mannose glycosylation, while optionally and
preferably targeting (and/or otherwise manipulating processing of)
such proteins with an ER signal. Without wishing to be limited by a
single hypothesis, it is believed that such targeting causes the
proteins to by-pass the Golgi body and thereby to retain the
desired glycosylation, particularly high mannose glycosylation. It
should be noted that the term "plant culture" as used herein
includes any type of transgenic and/or otherwise genetically
engineered plant cell that is grown in culture. The genetic
engineering may optionally be permanent or transient. Preferably,
the culture features cells that are not assembled to form a
complete plant, such that at least one biological structure of a
plant is not present. Optionally and preferably, the culture may
feature a plurality of different types of plant cells, but
preferably the culture features a particular type of plant cell. It
should be noted that optionally plant cultures featuring a
particular type of plant cell may be originally derived from a
plurality of different types of such plant cells.
[0020] The plant cells may be grown according to any type of
suitable culturing method, including but not limited to, culture on
a solid surface (such as a plastic culturing vessel or plate for
example) or in suspension.
[0021] The invention further relates to vectors and methods for
expression and production of enzymatically active high mannose
lysosomal enzymes using transgenic plant root, particularly carrot
cells. More particularly, the invention relates to host cells,
particularly transgenic suspended carrot cells, vectors and methods
for high yield expression and production of biologically active
high mannose Glucocerebrosidase (GCD). The invention further
provides for compositions and methods for the treatment of
lysosomal storage diseases.
[0022] The present invention is also of a device, system and method
for providing sufficient quantities of biologically active
lysosomal enzymes, and particularly, human GCD, to deficient cells.
The present invention is also of host cells comprising new vector
compositions that allow for efficient production of genes encoding
lysosomal enzymes, such as GCD.
[0023] The present invention therefore solves a long-felt need for
an economically viable technology to produce proteins having
particular glycosylation requirements, such as the high mannose
glycosylation of lysosomal enzymes such as GCD for example. The
present invention is able to solve this long felt need by using
plant cell culture.
[0024] In order to further explain the present invention, a brief
explanation is now provided of the biosynthetic pathway of
high-mannose proteins. The basic biosynthesis pathway of
high-mannose and complex N-linked glycans is highly conserved among
all eukaryotes. Biosynthesis begins in the Endoplasmic Reticulum
(ER) with the transfer of the glycan precursor from a dolichol
lipid carrier to a specific Asn residue on the protein by the
oligosaccharyl transferase. The precursor is subsequently modified
in the ER by glycosidases I and II and a hypothetical mannosidase
to yield the high mannose structures, similar to the process
occurring in mammals.
[0025] Further modifications of the glycan sequence to complex and
hybrid structures occur in the Golgi. Such modifications include
removal of one of the four mannose residues by .alpha.-mannosidase
I, addition of an N-acetylglucosamine residue, removal of the two
additional mannose residues by .alpha.-mannosidase II, addition of
N-acetylglucosamine and optionally, at this stage, xylose and
fucose residues may be added to yield plant specific N-linked
glycans. After the transfer of xylose and fucose to the core,
complex type N-glycans can be further processed via the addition of
terminal fucose and galactose. Further modifications may take place
during the glycoprotein transport.
[0026] Several approaches are currently used in the background art
to control and tailor protein glycosylation in plants, all of which
have significant deficiencies, particularly in comparison to the
present invention. Gross modifications, such as complete inhibition
of glycosylation or the removal of glycosylation sites from the
peptide chain is one strategy. However, this approach can result in
structural defects. An additional approach involves knock-out and
introduction of specific carbohydrate processing enzymes. Again,
this approach is difficult and may also have detrimental effects on
the plant cells themselves.
[0027] The present invention overcomes these deficiencies of the
background art approaches by using an ER signal and/or by blocking
secretion from the ER to the Golgi body. Without wishing to be
limited by a single hypothesis, since a high mannose structure of
lysosomal enzymes is preferred, if secretion can be blocked and the
protein can be maintained in the ER, naturally occurring high
mannose structures are obtained without the need for
remodeling.
[0028] As indicated above, proteins transported via the
endomembrane system first pass into the endoplasmic reticulum. The
necessary transport signal for this step is represented by a signal
sequence at the N-terminal end of the molecule, the so-called
signal peptide. As soon as this signal peptide has fulfilled its
function, which is to insert the precursor protein attached to it
into the endoplasmic reticulum, it is split off proteolytically
from the precursor protein. By virtue of its specific function,
this type of signal peptide sequence has been conserved to a high
degree during evolution in all living cells, irrespective of
whether they are bacteria, yeasts, fungi, animals or plants.
[0029] Many plant proteins, which are inserted into the endoplasmic
reticulum by virtue of the signal peptide do not reside in the ER,
but are transported from the endoplasmic reticulum to the Golgi and
continue trafficking from the Golgi to the vacuoles. One class of
such sorting signals for this traffic resides are signals that
reside on the C-terminal part of the precursor protein [Neuhaus and
Rogers, (1998) Plant Mol. Biol. 38:127-144]. Proteins containing
both an N-terminal signal peptide for insertion into the
endoplasmic reticulum and a C-terminal vacuolar targeting signal
are expected to contain complex glycans, which is attached to them
in the Golgi [Lerouge et al., (1998) Plant Mol. Biol. 38:31-48].
The nature of such C-terminal sorting signals can vary very widely.
U.S. Pat. No. 6,054,637 describes peptide fragments obtained from
the region of tobacco basic chitinase, which is a vacuolar protein
that act as vacuolar targeting peptides. An example for a vacuolar
protein containing a C-terminal targeting signal and complex
glycans is the phaseolin storage protein from bean seeds [Frigerio
et al., (1998) Plant Cell 10:1031-1042; Frigerio et al., (2001)
Plant Cell 13:1109-1126.].
[0030] The paradigm is that in all eukaryotic cells vacuolar
proteins pass via the ER and the Golgi before sequestering in the
vacuole as their final destination. Surprisingly, the transformed
plant root cells of the present invention produced an unexpected
high mannose GCD. Advantageously, this high mannose product was
found to be biologically active and therefore no further steps were
needed for its activation. Without wishing to be limited by a
single hypothesis, it would appear that the use of an ER signal
with the recombinant protein being produced in plant cell culture
was able to overcome transportation to the Golgi, and hence to
retain the desired high mannose glycosylation. Optionally, any type
of mechanism which is capable to produce high mannose
glycosylation, including any type of mechanism to by-pass the
Golgi, may be used in accordance with the present invention.
[0031] In a first aspect, the present invention relates to a host
cell producing a high mannose recombinant protein of interest. This
cell may be transformed or transfected with a recombinant nucleic
acid molecule encoding a protein of interest or with an expression
vector comprising the nucleic acid molecule. Such nucleic acid
molecule comprises a first nucleic acid sequence encoding the
protein of interest operably linked to a second nucleic acid
sequence encoding a vacuolar targeting signal peptide. The first
nucleic acid sequence may be optionally further operably linked to
a third nucleic acid sequence encoding an ER (endoplasmic
reticulum) targeting signal peptide. The host cell of the invention
is characterized in that the protein of interest is produced by the
cell in a highly mannosylated form.
[0032] The host cell of the invention may be a eukaryotic or
prokaryotic cell.
[0033] In one embodiment, the host cell of the invention is a
prokaryotic cell, preferably, a bacterial cell, most preferably, an
Agrobacterium tumefaciens cell. These cells are used for infecting
the preferred plant host cells described below.
[0034] In another preferred embodiment, the host cell of the
invention may be a eukaryotic cell, preferably, a plant cell, and
most preferably, a plant root cell selected from the group
consisting of Agrobacterium rihzogenes transformed root cell,
celery cell, ginger cell, horseradish cell and carrot cell.
[0035] In a preferred embodiment, the plant root cell is a carrot
cell. It should be noted that the transformed carrot cells of the
invention are grown in suspension. As mentioned above and described
in the Examples, these cells were transformed with the
Agrobacterium tumefaciens cells.
[0036] In another embodiment, the recombinant nucleic acid molecule
comprised within the host cell of the invention, comprises a first
nucleic acid sequence encoding a lysosomal enzyme that is in
operable linkage with a second nucleic acid sequence encoding a
vacuolar targeting signal peptide derived from the basic tobacco
chitinase A gene. This vacuolar signal peptide has the amino acid
sequence as denoted by SEQ ID NO: 2. The first nucleic acid
sequence may be optionally further linked in an operable linkage
with a third nucleic acid sequence encoding an ER (endoplasmic
reticulum) targeting signal peptide as denoted by SEQ ID NO: 1. In
one embodiment, the recombinant nucleic acid molecule comprised
within the host cell of the invention further comprises a promoter
that is functional in plant cells. This promoter should be operably
linked to the recombinant molecule of the invention.
[0037] In another embodiment, this recombinant nucleic acid
molecule may optionally further comprise an operably linked
terminator which is preferably functional in plant cells. The
recombinant nucleic acid molecule of the invention may optionally
further comprise additional control, promoting and regulatory
elements and/or selectable markers. It should be noted that these
regulatory elements are operably linked to the recombinant
molecule.
[0038] In a preferred embodiment, the high mannose protein of
interest produced by the host cell of the invention may be a high
mannose glycoprotein having exposed mannose terminal residues.
[0039] Such high mannose protein may be according to another
preferred embodiment, a lysosomal enzyme selected from the group
consisting of glucocerebrosidase (GCD), acid sphingomyelinase,
hexosaminidase, .alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase. In a
preferred embodiment, the lysosomal enzyme may be the human
glucocerebrosidase (GCD). Hereinafter recombinant GCD, rGCD, rhGCD
all refer to various forms of recombinant human GCD unless
otherwise indicated.
[0040] As previously described, Gaucher's disease, the most
prevalent lysosomal storage disorder, is caused by point mutations
in the hGCD (human glucocerebrosidase) gene (GBA), which result in
accumulation of GlcCer in the lysosomes of macrophages. The
identification of GCD deficiency as the primary cause of Gaucher's
disease led to the development of enzyme replacement therapy as a
therapeutic strategy for this disorder. However, glycosylation
plays a crucial role in hGCD activity and uptake to target
cells.
[0041] Therefore, according to other preferred embodiments of the
present invention, suitably glycosylated hGCD is preferably
provided by controlling the expression of hGCD in plant cell
culture, optionally and more preferably by providing an ER signal
and/or otherwise by optionally and more preferably blocking
transportation to the Golgi.
[0042] Optionally and preferably, the hGCD has at least one
oligosaccharide chain comprising an exposed mannose residue for the
treatment or prevention of Gaucher's disease.
[0043] Still further, in a particular embodiment, this preferred
host cell is transformed or transfected by a recombinant nucleic
acid molecule which further comprises an .sup.35S promoter from
Cauliflower Mosaic Virus, an octopine synthase terminator of
Agrobacterium tumefaciens and TMV (Tobacco Mosaic Virus) omega
translational enhancer element. According to a preferred
embodiment, this recombinant nucleic acid molecule comprises the
nucleic acid sequence substantially as denoted by SEQ ID NO: 13 and
encodes a high mannose GCD having the amino acid sequence
substantially as denoted by SEQ ID NOs: 14 or 15.
[0044] It should be appreciated that the present invention further
provides for an expression vector comprising a nucleic acid
molecule encoding a biologically active lysosomal enzyme.
[0045] In one preferred embodiment, the expression vector of the
invention comprises a nucleic acid molecule encoding a biologically
active high mannose human glucocerebrosidase (GCD). Preferably,
this preferred expression vector comprises a nucleic recombinant
nucleic acid molecule which having the nucleic acid sequence
substantially as denoted by SEQ ID NO: 13.
[0046] In a second aspect, the present invention relates to a
recombinant high mannose protein produced by the host cell of the
invention.
[0047] In a preferred embodiment, this high mannose protein may be
a biologically active high mannose lysosomal enzyme selected from
the group consisting of glucocerebrosidase (GCD), acid
sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase. Most
preferably, this lysosomal enzyme may be human glucocerebrosidase
(GCD).
[0048] Still further, the invention provides for a recombinant
biologically active high mannose lysosomal enzyme having at least
one oligosaccharide chain comprising an exposed mannose
residue.
[0049] According to a preferred embodiment, the recombinant
lysosomal enzyme of the invention can bind to a mannose receptor on
a target cell in a target site. Preferably, this site may be within
a subject suffering from a lysosomal storage disease.
[0050] It should be noted that the recombinant lysosomal enzyme has
increased affinity for the target cell, in comparison with the
corresponding affinity of a naturally occurring lysosomal enzyme
for the target cell. In a specific embodiment, the target cell at
the target site may be a Kupffer cell in the liver of the
subject.
[0051] In a preferred embodiment, the recombinant lysosomal enzyme
may be selected from the group consisting of glucocerebrosidase
(GCD), acid sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase or sialidase.
[0052] Most preferably, this recombinant lysosomal enzyme is
glucocerebrosidase (GCD).
[0053] In a third aspect, the invention relates to a method of
producing a high mannose protein. Accordingly, the method of the
invention comprises the steps of: (a) preparing a culture of
recombinant host cells transformed or transfected with a
recombinant nucleic acid molecules encoding a recombinant protein
of interest or with an expression vector comprising the recombinant
nucleic acid molecules; (b) culturing these host cell culture
prepared by step (a) under conditions permitting the expression of
the protein, wherein the host cells produce the protein in a highly
mannosylated form; (c) recovering the protein from the cells and
harvesting the cells from the culture provided in (a); and (d)
purifying the protein of step (c) by a suitable protein
purification method.
[0054] According to a preferred embodiment, the host cell used by
this method is the host cell of the invention.
[0055] In another preferred embodiment, the high mannose protein
produced by the method of the invention may be a biologically
active high mannose lysosomal enzyme having at least one
oligosaccharide chain comprising an exposed mannose residue.
[0056] This recombinant enzyme can bind to a mannose receptor on a
target cell in a target site. More particularly, the recombinant
enzyme produced by the method of the invention has increased
affinity for the target cell, in comparison with the corresponding
affinity of a naturally occurring lysosomal enzyme to the target
cell. Accordingly, the target cell at the target site may be
Kupffer cell in the liver of the subject.
[0057] In a specific embodiment, this lysosomal enzyme may be
selected from the group consisting of glucocerebrosidase (GCD),
acid sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase. Most
preferably, this lysosomal enzyme may be glucocerebrosidase
(GCD).
[0058] In another preferred embodiment, the host cell used by the
method of the invention may be a plant root cell selected from the
group consisting of Agrobacterium rihzogenes transformed root cell,
celery cell, ginger cell, horseradish cell and carrot cell. Most
preferably, the plant root cell is a carrot cell. It should be
particularly noted that in the method of the invention, the
transformed host carrot cells are grown in suspension.
[0059] In a further aspect, the present invention relates to a
method for treating a subject having lysosomal storage disease
using exogenous recombinant lysosomal enzyme, comprising: (a)
providing a recombinant biologically active form of lysosomal
enzyme purified from transformed plant root cells, and capable of
efficiently targeting cells abnormally deficient in the lysosomal
enzyme. This recombinant biologically active enzyme has exposed
terminal mannose residues on appended oligosaccharides; and (b)
administering a therapeutically effective amount of the recombinant
biologically active lysosomal enzyme to the subject. In a preferred
embodiment, the recombinant high mannose lysosomal enzyme used by
the method of the invention may be produced by the host cell of the
invention. Preferably, this host cell is a carrot cell.
[0060] In another preferred embodiment, the lysosomal enzyme used
by the method of the invention may be a high mannose enzyme
comprising at least one oligosaccharide chain having an exposed
mannose residue. This recombinant enzyme can bind to a mannose
receptor on a target cell in a target site within a subject. More
preferably, this recombinant lysosomal enzyme has increased
affinity for these target cells, in comparison with the
corresponding affinity of a naturally occurring lysosomal enzyme to
the target cell.
[0061] More specifically, the lysosomal enzyme used by the method
of the invention may be selected from the group consisting of
glucocerebrosidase (GCD), acid sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase or sialidase. Preferably,
this lysosomal enzyme is glucocerebrosidase (GCD).
[0062] According to a preferred embodiment, the method of the
invention is therefore intended for the treatment of a lysosomal
storage disease, particularly Gaucher's disease.
[0063] In such case the target cell at the target site may be a
Kupffer cell in the liver of the subject.
[0064] The invention further provides for a pharmaceutical
composition for the treatment of a lysosomal storage disease
comprising as an active ingredient a recombinant biologically
active high mannose lysosomal enzyme as defined by the invention.
The composition of the invention may optionally further comprise
pharmaceutically acceptable diluent, carrier or excipient.
[0065] In a specific embodiment, the composition of the invention
is intended for the treatment of Gaucher's disease. Such
composition may preferably comprise as an effective ingredient a
biologically active high mannose human glucocerebrosidase (GCD), as
defined by the invention.
[0066] The invention further relates to the use of a recombinant
biologically active high mannose lysosomal enzyme of the invention
in the manufacture of a medicament for the treatment or prevention
of a lysosomal storage disease. More particularly, such disease may
be Gaucher's disease.
[0067] Accordingly, this biologically active lysososomal enzyme is
a biologically active high mannose human glucocerebrosidase (GCD),
as defined by the invention.
[0068] According to the present invention, there is provided a host
cell producing a high mannose recombinant protein, comprising a
polynucleotide encoding the recombinant protein and a signal for
causing the recombinant protein to be produced as a high mannose
protein. Preferably, the polynucleotide comprises a first nucleic
acid sequence encoding the protein of interest operably linked to a
second nucleic acid sequence encoding a signal peptide. Optionally,
the signal peptide comprises an ER (endoplasmic reticulum)
targeting signal peptide. Preferably, the polynucleotide further
comprises a third nucleic acid sequence for encoding a vacuolar
targeting signal peptide.
[0069] Preferably, the signal causes the recombinant protein to be
targeted to the ER. More preferably, the signal comprises a signal
peptide for causing the recombinant protein to be targeted to the
ER. Most preferably, the polynucleotide comprises a nucleic acid
segment for encoding the signal peptide.
[0070] Optionally and preferably, the signal causes the recombinant
protein to by-pass the Golgi. Preferably, the signal comprises a
signal peptide for causing the recombinant protein to not be
targeted to the Golgi. More preferably, the polynucleotide
comprises a nucleic acid segment for encoding the signal
peptide.
[0071] Optionally and preferably, the host cell is any one of a
eukaryotic and a prokaryotic cell. Optionally, the prokaryotic cell
is a bacterial cell, preferably an Agrobacterium tumefaciens cell.
Preferably, the eukaryotic cell is a plant cell. More preferably,
the plant cell is a plant root cell selected from the group
consisting of Agrobacterium rihzogenes transformed root cell,
celery cell, ginger cell, horseradish cell and carrot cell. Most
preferably, the plant root cell is a carrot cell.
[0072] Preferably, the recombinant polynucleotide comprises a first
nucleic acid sequence encoding the protein of interest that is in
operable link with a second nucleic acid sequence encoding a
vacuolar targeting signal peptide derived from the basic tobacco
chitinase A gene, which vacuolar signal peptide has the amino acid
sequence as denoted by SEQ ID NO: 2, wherein the first nucleic acid
sequence is optionally further operably linked to a third nucleic
acid sequence encoding an ER (endoplasmic reticulum) targeting
signal peptide as denoted by SEQ ID NO: 1.
[0073] More preferably, the recombinant polynucleotide further
comprises a promoter that is functional in plant cells, wherein the
promoter is operably linked to the recombinant molecule.
[0074] Most preferably, the recombinant polynucleotide further
comprises a terminator that is functional in plant cells, wherein
the terminator is operably linked to the recombinant molecule.
[0075] Also most preferably, the recombinant polynucleotide
optionally further comprises additional control, promoting and
regulatory elements and/or selectable markers, wherein the
regulatory elements are operably linked to the recombinant
molecule.
[0076] Preferably, the high mannose protein is a high mannose
glycoprotein having glycosylation with at least one exposed mannose
residue. More preferably, the high mannose protein is a
biologically active high mannose lysosomal enzyme selected from the
group consisting of glucocerebrosidase (GCD), acid
sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase
[0077] Most preferably, the lysosomal enzyme is human
glucocerebrosidase (GCD).
[0078] Preferably, the GCD comprises the amino acid sequence
substantially as denoted by SEQ ID NO: 8, encoded by the nucleic
acid sequence as denoted by SEQ ID NO: 7.
[0079] More preferably, the cell is transformed or transfected with
a recombinant polynucleotide or with an expression vector
comprising the molecule, which recombinant polynucleotide further
comprises an .sup.35S promoter from Cauliflower Mosaic Virus, an
octopine synthase terminator of Agrobacterium tumefaciens, and the
regulatory element is the TMV (Tobacco Mosaic Virus) omega
translational enhancer element, and having the nucleic acid
sequence substantially as denoted by SEQ ID NO: 13 encoding GCD
having the amino acid sequence substantially as denoted by SEQ ID
NOs: 14 or 15.
[0080] According to preferred embodiments, there is provided a
recombinant high mannose protein produced by the host cell
described above.
[0081] Preferably, the high mannose protein is a biologically
active high mannose lysosomal enzyme selected from the group
consisting of glucocerebrosidase (GCD), acid sphingomyelinase,
hexosaminidase, .alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase.
[0082] More preferably, the lysosomal enzyme is human
glucocerebrosidase (GCD).
[0083] According to other preferred embodiments of the present
invention, there is provided a recombinant biologically active high
mannose lysosomal enzyme having at least one oligosaccharide chain
comprising an exposed mannose residue.
[0084] According to still other preferred embodiments, there is
provided a recombinant protein, comprising a first portion having
signal peptide activity and a second portion having lysosomal
enzyme activity, the first portion causing the second portion to be
processed in a plant cell with at least one oligosaccharide chain
comprising an exposed mannose residue.
[0085] Preferably, the lysosomal enzyme comprises a protein for the
treatment or prevention of Gaucher's disease.
[0086] More preferably, the protein comprises hGCD.
[0087] Preferably, the first portion comprises a plant cell ER
targeting signal peptide. More preferably, the recombinant enzyme
can bind to a mannose receptor on a target cell in a target site
within a subject suffering from a lysosomal storage disease. Most
preferably, the recombinant lysosomal enzyme has increased affinity
for the target cell, in comparison with the corresponding affinity
of a naturally occurring lysosomal enzyme for the target cell.
[0088] Also most preferably, the recombinant lysosomal enzyme is
selected from the group consisting of glucocerebrosidase (GCD),
acid sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase or sialidase.
[0089] Preferably, the recombinant lysosomal enzyme is
glucocerebrosidase (GCD).
[0090] Also preferably, the target cell at the target site is a
Kupffer cell in the liver of the subject.
[0091] According to still other preferred embodiments there is
provided a recombinant high mannose protein, produced in plant cell
culture. Preferably, the protein features a plant signal peptide
for targeting a protein to the ER.
[0092] More preferably, the plant signal peptide comprises a
peptide for targeting the protein to the ER in a root plant cell
culture. Most preferably, the root plant cell culture comprises
carrot cells.
[0093] According to yet other preferred embodiments there is
provided a recombinant high mannose hGCD protein, produced in plant
cell culture.
[0094] According to still other preferred embodiments there is
provided use of a plant cell culture for producing a high mannose
protein.
[0095] According to other preferred embodiments there is provided a
method of producing a high mannose protein comprising: preparing a
culture of recombinant host cells transformed or transfected with a
recombinant polynucleotide encoding for a recombinant protein;
culturing the host cell culture under conditions permitting the
expression of the protein, wherein the host cells produce the
protein in a highly mannosylated form.
[0096] Preferably, the host cell culture is cultured in suspension.
More preferably, the method further comprises purifying the
protein.
[0097] According to other preferred embodiments, the method is
performed with the host cell as previously described. Preferably,
the high mannose protein is a biologically active high mannose
lysosomal enzyme having at least one oligosaccharide chain
comprising an exposed mannose residue. More preferably, the
recombinant enzyme binds to a mannose receptor on a target cell in
a target site. Most preferably, the recombinant enzyme has
increased affinity for the target cell, in comparison with the
corresponding affinity of a naturally occurring lysosomal enzyme to
the target cell.
[0098] Preferably, the lysosomal enzyme is selected from the group
consisting of glucocerebrosidase (GCD), acid sphingomyelinase,
hexosaminidase, .alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase.
[0099] More preferably, the lysosomal enzyme is glucocerebrosidase
(GCD). Most preferably, the target cell at the target site is
Kupffer cell in the liver of the subject.
[0100] Preferably, the host cell is a plant root cell selected from
the group consisting of Agrobacterium rihzogenes transformed root
cell, celery cell, ginger cell, horseradish cell and carrot
cell.
[0101] More preferably, the plant root cell is a carrot cell.
[0102] Most preferably, the transformed host carrot cells are grown
in suspension.
[0103] According to still other preferred embodiments there is
provided a method for treating a subject having lysosomal storage
disease using exogenous recombinant lysosomal enzyme, comprising:
providing a recombinant biologically active form of lysosomal
enzyme purified from transformed plant root cells, and capable of
efficiently targeting cells abnormally deficient in the lysosomal
enzyme, wherein the recombinant biologically active enzyme has
exposed terminal mannose residues on appended oligosaccharides; and
administering a therapeutically effective amount of the recombinant
biologically active lysosomal enzyme to the subject. This method
may optionally be performed with any host cell and/or protein as
previous described.
[0104] Preferably, the recombinant enzyme can bind to a mannose
receptor on a target cell in a target site within a subject. More
preferably, the recombinant lysosomal enzyme has increased affinity
for the target cell, in comparison with the corresponding affinity
of a naturally occurring lysosomal enzyme to the target cell. Most
preferably, the lysosomal enzyme is selected from the group
consisting of glucocerebrosidase (GCD), acid sphingomyelinase,
hexosaminidase, .alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase or sialidase. Also most
preferably, the lysosomal enzyme is glucocerebrosidase (GCD).
[0105] Also most preferably, the lysosomal storage disease is
Gaucher's disease. Also most preferably, the target cell at the
target site is a Kupffer cell in the liver of the subject.
[0106] According to still other preferred embodiments there is
provided a pharmaceutical composition for the treatment of a
lysosomal storage disease comprising as an active ingredient a
recombinant biologically active high mannose lysosomal enzyme as
described above, which composition optionally further comprises
pharmaceutically acceptable diluent, carrier or excipient.
Preferably, the lysosomal storage disease is Gaucher's disease.
More preferably, the recombinant lysosomal enzyme is a biologically
active high mannose human glucocerebrosidase (GCD).
[0107] According to still other preferred embodiments there is
provided the use of a recombinant biologically active high mannose
lysosomal enzyme as described above, in the manufacture of a
medicament for the treatment or prevention of a lysosomal storage
disease. Preferably, the disease is Gaucher's disease. More
preferably, the biologically active lysososomal enzyme is a
biologically active high mannose human glucocerebrosidase
(GCD).
[0108] The invention will be further described on the hand of the
following figures, which are illustrative only and do not limit the
scope of the invention which is also defined by the appended
claims.
BRIEF DESCRIPTION OF THE FIGURES
[0109] The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the Office
upon request and payment of the necessary fee.
[0110] The invention is herein described, by way of example only,
with reference to the accompanying drawings, wherein:
[0111] FIGS. 1A-1B
[0112] FIG. 1A shows the resulting expression cassette comprising
.sup.35S promoter from Cauliflower Mosaic Virus, TMV (Tobacco
Mosaic Virus) omega translational enhancer element, ER targeting
signal, the human GCD sequence (also denoted by SEQ ID NO: 7),
vacuolar signal and octopine synthase terminator sequence from
Agrobacterium tumefaciens.
[0113] FIG. 1B shows a schematic map of pGreenII plasmid
backbone.
[0114] FIG. 2 shows Western blot analysis of hGCD transformed cell
extracts using anti hGCD specific antibody. Standard Cerezyme (lane
1) was used as a positive control, untransformed callus was used as
negative control (lane 2), various selected calli extracts are
shown in lanes 3-8.
[0115] FIG. 3A-3C shows the first step of purification of rhGCD on
a strong cation exchange resin (Macro-Prep high-S support,
Bio-Rad), packed in a XK column (2.6.times.20 cm). The column was
integrated with an AKTA prime system (Amersham Pharmacia Biotech)
that allows conductivity monitoring, pH and absorbency at 280 nm.
Elution of the rh-GCD was obtained with equilibration buffer
containing 600 mM NaCl. FIG. 3A represents a standard run of this
purification step. The fractions collected during the run were
monitored by enzyme activity assay, as shown by FIG. 3B, and tubes
exhibiting enzymatic activity (in the elution peak) were pooled.
FIG. 3C shows coomassie-blue stain of elution fractions assayed for
activity.
[0116] FIGS. 3D-3F show corresponding graphs as for FIGS. 3A-3C but
for the second column.
[0117] FIG. 4A-C: shows the final purification step of the
recombinant hGCD on a hydrophobic interaction resin (TSK gel,
Toyopearl Phenyl-650C, Tosoh Corp.), packed in a XK column
(2.6.times.20 cm). The column was integrated with an AKTA prime
system (Amersham Pharmacia Biotech) that allows conductivity
monitoring, pH and absorbency at 280 nm. The GCD elution pool from
the previous column was loaded at 6 ml/min followed by washing with
equilibration buffer until the UV absorbance reach the baseline.
The pure GCD was eluted by 10 mM citric buffer containing 50%
ethanol.
[0118] FIG. 4A represents a standard run of this purification
step.
[0119] FIG. 4B shows the fractions collected during the run that
were monitored by enzyme activity assay.
[0120] FIG. 4C shows coomassie-blue stain of elution fractions
assayed for activity.
[0121] FIG. 5 shows activity of recombinant hGCD following uptake
by peritoneal macrophages (FIGS. 5A-5C), while FIG. 5D shows a
Western blot of recombinant GCD according to the present
invention.
[0122] FIG. 6 shows comparative glycosylation structures for rGCD
according to the present invention and that of Cerezyme.TM..
[0123] FIG. 7 shows glycosylation structures for rGCD according to
the present invention.
[0124] FIGS. 8a-8d shows additional N-glycan glycosylation
structures for rGCD according to the present invention.
[0125] FIGS. 9a-9b show the antigenic and electrophoretic identity
of purified recombinant human GCD of the present invention and a
commercial human GCD (Cerezyme.RTM.) recombinantly produced in
mammalian CHO cells. FIG. 9a is a Coomassie blue stained SDS-PAGE
analysis of the plant produced hGCD of the invention (lanes 1 and
2, 5 and 10 .mu.g of protein, respectively) and Cerezyme.RTM.,
(lanes 3 and 4, 5 and 10 .mu.g protein, respectively). FIG. 9b is a
Western blot analysis of SDS-PAGE separated recombinant human GCD
(lanes 1 and 2, 50 and 10 ng respectively) of the present invention
compared to the commercial Cerezyme.RTM. enzyme. SDS-PAGE-separated
proteins were blotted onto nitrocellulose (lanes 3 and 4, 50 and
100 ng antigen, respectively), and immunodetected using a
polyclonal anti-GCD antibody and peroxidase-conjugated goat
anti-rabbit HRP secondary antibody. Note the consistency of size
and immune reactivity between the plant recombinant GCD of the
present invention and the mammalian-cell (CHO) prepared enzyme
(Cerezyme.RTM.). MW=molecular weight standard markers.
[0126] FIGS. 10a-10b are schematic representations of the glycan
structures of the recombinant human GCD of the present invention.
FIG. 10a shows the results of a major glycan structure analysis of
the GCD, indicating all structures and their relative amounts based
on HPLC, enzyme array digests and MALDI. Retention time of
individual glycans is compared to the retention times of a standard
partial hydrolysis of dextran giving a ladder of glucose units
(GU). FIG. 10b shows the glycan structures of the mammalian-cell
(CHO) prepared enzyme (Cerezyme.RTM.), before and after the
in-vitro modification process. Note the predominance of the xylose
and exposed mannose glycosides in the recombinant human GCD of the
present invention;
[0127] FIG. 11 is a HP-anion exchange chromatography analysis of
the gycan profile of the recombinant human GCD of the present
invention, showing the consistent and reproducible glycan structure
of recombinant human GCD from batch to batch.
[0128] FIG. 12 is a kinetic analysis showing the identical
catalytic kinetics characteristic of both recombinant human GCD of
the invention (open triangles) and the mammalian-cell (CHO)
prepared enzyme (Cerezyme.RTM.) (closed squares). Recombinant human
GCD of the invention and Cerezyme.RTM. (0.2 ng) were assayed using
C6-NBDGlcCer (5 min, 37.degree. C.) in MES buffer (50 mM, pH 5.5).
Michaelis-Menten kinetics was analyzed using GraphPad Prism
software. Data are means of two independent experiments.
DETAILED DESCRIPTION OF THE INVENTION
[0129] Proteins for pharmaceutical use have been traditionally
produced in mammalian or bacterial expression systems. In the past
few years a promising new expression system was found in plants.
Due to the relative simplicity of introducing new genes and
potential for mass production of proteins and peptides, `molecular
pharming` is becoming increasingly popular as a protein expression
system.
[0130] One of the major differences between mammalian and plant
protein expression system is the variation of protein glycosylation
sequences, caused by the differences in biosynthetic pathways.
Glycosylation was shown to have a profound effect on activity,
folding, stability, solubility, susceptibility to proteases, blood
clearance rate and antigenic potential of proteins. Hence, any
protein production in plants should take into consideration the
potential ramifications of plant glycosylation.
[0131] This is well illustrated by the difficulties encountered in
previous attempts to produce biologically active mammalian proteins
in plants. For example, U.S. Pat. No. 5,929,304, to Radin et al
(Crop Tech, Inc) discloses the production, in tobacco plants, of a
human .alpha.-L-iduronase (IDUA) and a glucocerebrosidase (hGC), by
insertion of the relevant human lysosomal enzyme coding sequences
into an expression cassette for binary plasmid for A.
tumefaciens-mediated transformation of tobacco plants. Despite
demonstration of recombinant human lysosomal protein production in
the transgenic plants, and the detection of catalytic activity in
the recombinant protein, no binding to or uptake into target cells
was disclosed, and the lysosomal enzyme compositions remained
unsuitable for therapeutic applications, presumably due to the
absence of accurate glycosylation of the protein, and subsequent
inability of the polypeptides to interact efficiently with their
target cells/tissue though a specific receptor.
[0132] Carbohydrate moiety is one of the most common
post-translational modifications of proteins. Protein glycosylation
is divided into two categories: N-linked and O-linked. The two
types differ in amino acid to which the glycan moity is attached on
protein --N-linked are attached to Asn residues, while O-linked are
attached to Ser or Thr residues. In addition, the glycan sequences
of each type bears unique distinguishing features. Of the two
types, N-linked glycosylation is the more abundant, and its effect
on proteins has been extensively studied. O-linked glycans, on
other hand are relatively scarce, and less information is available
regarding their influence on proteins. The majority of data
available on protein glycosylation in plants focuses on N-linked,
rather than O-linked glycans.
[0133] The present invention describes herein a plant expression
system based on transgenic plant cells, which are preferably root
cells, optionally and preferably grown in suspension. This
expression system is particularly designed for efficient production
of a high mannose protein of interest. The term "high mannose"
includes glycosylation having at least one exposed mannose
residue.
[0134] Thus, in a first aspect, the present invention relates to a
host cell producing a high mannose recombinant protein of interest.
Preferably, the recombinant protein features an ER (endoplasmic
reticulum) signal peptide, more preferably an ER targeting signal
peptide. Alternatively or additionally, the recombinant protein
features a signal that causes the protein to by-pass the Golgi. The
signal preferably enables the recombinant protein to feature high
mannose glycosylation, more preferably by retaining such
glycosylation, and most preferably by targeting the ER and/or by
by-passing the Golgi. As described in greater detail herein, such a
signal is preferably implemented as a signal peptide, which more
preferably forms part of the protein sequence, optionally and more
preferably through engineering the protein to also feature the
signal peptide as part of the protein. It should be noted that the
signal may optionally be a targeting signal, a retention signal, an
avoidance (by-pass) signal, or any combination thereof, or any
other type of signal capable of providing the desired high mannose
glycosylation structure.
[0135] Without wishing to be limited by a single hypothesis, it
would appear that the use of an ER targeting signal with the
recombinant protein being produced in plant cell culture was able
to overcome transportation to the Golgi, and hence to retain the
desired high mannose glycosylation. Optionally, any type of
mechanism which is capable to produce high mannose glycosylation,
including any type of mechanism to by-pass the Golgi, may be used
in accordance with the present invention. ER targeting signal
peptides are well known in the art; they are N-terminal signal
peptides. Optionally any suitable ER targeting signal peptide may
be used with the present invention.
[0136] A host cell according to the present invention may
optionally be transformed or transfected (permanently and/or
transiently) with a recombinant nucleic acid molecule encoding a
protein of interest or with an expression vector comprising the
nucleic acid molecule. Such nucleic acid molecule comprises a first
nucleic acid sequence encoding the protein of interest, optionally
and preferably operably linked to a second nucleic acid sequence
encoding a vacuolar targeting signal peptide. It should be noted
that as used herein, the term "operably" linked does not
necessarily refer to physical linkage. The first nucleic acid
sequence may optionally and preferably further be operably linked
to a third nucleic acid sequence encoding an ER (endoplasmic
reticulum) targeting signal peptide. In one embodiment, the cell of
the invention is characterized in that the protein of interest is
produced by the cell in a form that includes at least one exposed
mannose residue, but is preferably a highly mannosylated form. In a
more preferred embodiment, the cell of the protein of interest is
produced by the cell in a form that includes an exposed mannose and
at least one xylose residue, in yet a more preferred embodiment, in
a form that further includes an exposed mannose and at least one
fucose residue. In a most preferred embodiment, the protein is
produced by the cell in a form that includes an exposed mannose, a
core .alpha. (1,2) xylose residue and a core .alpha.-(1,3) fucose
residue.
[0137] "Cells", "host cells" or "recombinant host cells" are terms
used interchangeably herein. It is understood that such terms refer
not only to the particular subject cells but to the progeny or
potential progeny of such a cell. Because certain modifications may
occur in succeeding generation due to either mutation or
environmental influences, such progeny may not, in fact, be
identical to the parent cell, but are still included within the
scope of the term as used herein. "Cell" or "host cell" as used
herein refers to cells which can be transformed with naked DNA or
expression vectors constructed using recombinant DNA techniques. As
used herein, the term "transfection" means the introduction of a
nucleic acid, e.g., naked DNA or an expression vector, into a
recipient cells by nucleic acid-mediated gene transfer.
"Transformation", as used herein, refers to a process in which a
cell's genotype is changed as a result of the cellular uptake of
exogenous DNA or RNA, and, for example, the transformed cell
expresses a recombinant form of the desired protein.
[0138] It should be appreciated that a drug resistance or other
selectable marker is intended in part to facilitate the selection
of the transformants. Additionally, the presence of a selectable
marker, such as drug resistance marker may be of use in keeping
contaminating microorganisms from multiplying in the culture
medium. Such a pure culture of the transformed host cell would be
obtained by culturing the cells under conditions which are required
for the induced phenotype's survival.
[0139] As indicated above, the host cells of the invention may be
transfected or transformed with a nucleic acid molecule. As used
herein, the term "nucleic acid" refers to polynucleotides such as
deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic
acid (RNA). The terms should also be understood to include, as
equivalents, analogs of either RNA or DNA made from nucleotide
analogs, and, as applicable to the embodiment being described,
single-stranded (such as sense or antisense) and double-stranded
polynucleotides.
[0140] In yet another embodiment, the cell of the invention may be
transfected or transformed with an expression vector comprising the
recombinant nucleic acid molecule. "Expression Vectors", as used
herein, encompass vectors such as plasmids, viruses, bacteriophage,
integratable DNA fragments, and other vehicles, which enable the
integration of DNA fragments into the genome of the host.
Expression vectors are typically self-replicating DNA or RNA
constructs containing the desired gene or its fragments, and
operably linked genetic control elements that are recognized in a
suitable host cell and effect expression of the desired genes.
These control elements are capable of effecting expression within a
suitable host. Generally, the genetic control elements can include
a prokaryotic promoter system or a eukaryotic promoter expression
control system. Such system typically includes a transcriptional
promoter, an optional operator to control the onset of
transcription, transcription enhancers to elevate the level of RNA
expression, a sequence that encodes a suitable ribosome binding
site, RNA splice junctions, sequences that terminate transcription
and translation and so forth. Expression vectors usually contain an
origin of replication that allows the vector to replicate
independently of the host cell.
[0141] Plasmids are the most commonly used form of vector but other
forms of vectors which serves an equivalent function and which are,
or become, known in the art are suitable for use herein. See, e.g.,
Pouwels et al. Cloning Vectors: a Laboratory Manual (1985 and
supplements), Elsevier, N.Y.; and Rodriquez, et al. (eds.) Vectors:
a Survey of Molecular Cloning Vectors and their Uses, Buttersworth,
Boston, Mass. (1988), which are incorporated herein by
reference.
[0142] In general, such vectors contain, in addition, specific
genes which are capable of providing phenotypic selection in
transformed cells. The use of prokaryotic and eukaryotic viral
expression vectors to express the genes coding for the polypeptides
of the present invention are also contemplated.
[0143] Optionally, the vector may be a general plant vector (as
described with regard to the Examples below). Alternatively, the
vector may optionally be specific for root cells.
[0144] In one preferred embodiment, the cell of the invention may
be a eukaryotic or prokaryotic cell.
[0145] In a specific embodiment, the cell of the invention is a
prokaryotic cell, preferably, a bacterial cell, most preferably, an
Agrobacterium tumefaciens cell. These cells are used for infecting
the preferred plant host cells described below.
[0146] In another preferred embodiment, the cell of the invention
may be a eukaryotic cell, preferably, a plant cell, and most
preferably, a plant root cell selected from the group consisting of
Agrobacterium rihzogenes transformed plant root cell, celery cell,
ginger cell, horseradish cell and carrot cell.
[0147] In a preferred embodiment, the plant root cell is a carrot
cell. It should be noted that the transformed carrot cells of the
invention are grown in suspension. As mentioned above and described
in the Examples, these cells were transformed with the
Agrobacterium tumefaciens cells of the invention.
[0148] The expression vectors or recombinant nucleic acid molecules
used for transfecting or transforming the host cells of the
invention may be further modified according to methods known to
those skilled in the art to add, remove, or otherwise modify
peptide signal sequences to alter signal peptide cleavage or to
increase or change the targeting of the expressed lysosomal enzyme
through the plant endomembrane system. For example, but not by way
of limitation, the expression construct can be specifically
engineered to target the lysosomal enzyme for secretion, or
vacuolar localization, or retention in the endoplasmic reticulum
(ER).
[0149] In one embodiment, the expression vector or recombinant
nucleic acid molecule, can be engineered to incorporate a
nucleotide sequence that encodes a signal targeting the lysosomal
enzyme to the plant vacuole. For example, and not by way of
limitation, the recombinant nucleic acid molecule comprised within
the host cell of the invention, comprises a first nucleic acid
sequence encoding a lysosomal enzyme that is in operable linkage
with a second nucleic acid sequence encoding a vacuolar targeting
signal peptide derived from the basic tobacco chitinase A gene.
This vacuolar signal peptide has the amino acid sequence as denoted
by SEQ ID NO: 2. The first nucleic acid sequence may be optionally
further linked in an operable linkage with a third nucleic acid
sequence encoding an ER (endoplasmic reticulum) targeting signal
peptide as denoted by SEQ ID NO: 1. In one embodiment, the
recombinant nucleic acid molecule comprised within the host cell of
the invention further comprises a promoter that is functional in
plant cells. This promoter should be operably linked to the
recombinant molecule of the invention.
[0150] The term "operably linked" is used herein for indicating
that a first nucleic acid sequence is operably linked with a second
nucleic acid sequence when the first nucleic acid sequence is
placed in a functional relationship with the second nucleic acid
sequence. For instance, a promoter is operably linked to a coding
sequence if the promoter affects the transcription or expression of
the coding sequence. Optionally and preferably, operably linked DNA
sequences are contiguous (e.g. physically linked) and, where
necessary to join two protein-coding regions, in the same reading
frame. Thus, a DNA sequence and a regulatory sequence(s) are
connected in such a way as to permit gene expression when the
appropriate molecules (e.g., transcriptional activator proteins)
are bound to the regulatory sequence(s).
[0151] In another embodiment, this recombinant nucleic acid
molecule may optionally further comprise an operably linked
terminator which is preferably functional in plant cells. The
recombinant nucleic acid molecule of the invention may optionally
further comprise additional control, promoting and regulatory
elements and/or selectable markers. It should be noted that these
regulatory elements are operably linked to the recombinant
molecule.
[0152] Regulatory elements that may be used in the expression
constructs include promoters which may be either heterologous or
homologous to the plant cell. The promoter may be a plant promoter
or a non-plant promoter which is capable of driving high levels
transcription of a linked sequence in plant cells and plants.
Non-limiting examples of plant promoters that may be used
effectively in practicing the invention include cauliflower mosaic
virus (CaMV) .sup.35S, rbcS, the promoter for the chlorophyll a/b
binding protein, AdhI, NOS and HMG2, or modifications or
derivatives thereof. The promoter may be either constitutive or
inducible. For example, and not by way of limitation, an inducible
promoter can be a promoter that promotes expression or increased
expression of the lysosomal enzyme nucleotide sequence after
mechanical gene activation (MGA) of the plant, plant tissue or
plant cell.
[0153] The expression vectors used for transfecting or transforming
the host cells of the invention can be additionally modified
according to methods known to those skilled in the art to enhance
or optimize heterologous gene expression in plants and plant cells.
Such modifications include but are not limited to mutating DNA
regulatory elements to increase promoter strength or to alter the
protein of interest.
[0154] In a preferred embodiment, the high mannose protein of
interest produced by the host cell of the invention may be a high
mannose glycoprotein having at least one exposed mannose residue
(at least one terminal mannose residue).
[0155] Such high mannose protein may be according to another
preferred embodiment, a lysosomal enzyme selected from the group
consisting of glucocerebrosidase (GCD), acid sphingomyelinase,
hexosaminidase, .alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase.
[0156] The term "lysosomal enzyme", as used herein with respect to
any such enzyme and product produced in a plant expression system
described by the invention, refers to a recombinant peptide
expressed in a transgenic plant cell from a nucleotide sequence
encoding a human or animal lysosomal enzyme, a modified human or
animal lysosomal enzyme, or a fragment, derivative or modification
of such enzyme. Useful modified human or animal lysosomal enzymes
include but are not limited to human or animal lysosomal enzymes
having one or several naturally occurring or artificially
introduced amino acid additions, deletions and/or
substitutions.
[0157] Soluble lysosomal enzymes share initial steps of
biosynthesis with secretory proteins, i.e., synthesis on the
ribosome, binding of the N-terminal signal peptide to the surface
of the rough endoplasmic reticulum (ER), transport into the lumen
of the ER where the signal peptide is cleaved, and addition of
oligosaccharides to specific asparagine residues (N-linked),
followed by further modifications of the nascent protein in the
Golgi apparatus [von Figura and Hasilik, Annu. Rev. Biochem.
55:167-193 (1986)]. The N-linked oligosaccharides can be complex,
diverse and heterogeneous, and may contain high-mannose residues.
The proteins undergo further processing in a post-ER, pre-Golgi
compartment and in the cis-Golgi to form either an N-linked mannose
6-phosphate (M-6-P) oligosaccharide-dependent or N-linked M-6-P
oligosaccharide-independent recognition signal for lysosomal
localized enzymes [Kornfeld & Mellman, Ann Rev. Cell Biol.,
5:483-525 (1989); Kaplan et al., Proc. Natl. Acad. Sci. USA 74:2026
(1977)]. The presence of the M-6-P recognition signal results in
the binding of the enzyme to M-6-P receptors (MPR). These bound
enzymes remain in the cell, are eventually packaged into lysosomes,
and are thus segregated from proteins targeted for secretion or to
the plasma membrane.
[0158] In a preferred embodiment, the lysosomal enzyme may be the
human glucocerebrosidase (GCD).
[0159] Still further, in a particular embodiment, this preferred
host cell is transformed or transfected by a recombinant nucleic
acid molecule which further comprises an .sup.35S promoter from
Cauliflower Mosaic Virus, preferably, having the nucleic acid
sequence as denoted by SEQ ID NO: 9, an octopine synthase
terminator of Agrobacterium tumefaciens, preferably, having the
nucleic acid sequence as denoted by SEQ ID NO: 12 and TMV (Tobacco
Mosaic Virus) omega translational enhancer element. According to a
preferred embodiment, this recombinant nucleic acid molecule
comprises the nucleic acid sequence substantially as denoted by SEQ
ID NO: 13 and encodes a high mannose GCD having the amino acid
sequence substantially as denoted by SEQ ID NOs: 14 or 15.
[0160] It should be appreciated that the present invention further
provides for an expression vector comprising a nucleic acid
molecule encoding a biologically active high mannose lysosomal
enzyme.
[0161] In one preferred embodiment of the aspect, the expression
vector of the invention comprises a nucleic acid molecule encoding
a biologically active high mannose human glucocerebrosidase (GCD).
Preferably, this preferred expression vector comprises a
recombinant nucleic acid molecule which having the nucleic acid
sequence substantially as denoted by SEQ ID NO: 13. According to a
specific embodiment, a preferred expression vector utilizes the
pGREEN II plasmid as described by the following Example 1.
[0162] It should be further noted, that the invention provides for
an expression cassette comprised within the expression vector
described above.
[0163] In a second aspect, the present invention relates to a
recombinant high mannose protein produced by the host cell of the
invention.
[0164] In a preferred embodiment, this high mannose protein may be
a biologically active high mannose lysosomal enzyme selected from
the group consisting of glucocerebrosidase (GCD), acid
sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase. Most
preferably, this lysosomal enzyme may be human glucocerebrosidase
(GCD).
[0165] The term "biologically active" is used herein with respect
to any recombinant lysosomal enzyme produced in a plant expression
system to mean that the recombinant lysosomal enzyme is able to
hydrolyze either the natural substrate, or an analogue or synthetic
substrate of the corresponding human or animal lysosomal enzyme, at
detectable levels.
[0166] Still further, the invention provides for a recombinant
biologically active high mannose lysosomal enzyme having at least
one oligosaccharide chain comprising an exposed mannose
residue.
[0167] According to a preferred embodiment, the recombinant
lysosomal enzyme of the invention can bind to a mannose receptor on
a target cell in a target site. Preferably, this site may be within
a subject suffering from a lysosomal storage disease.
[0168] Optionally and more preferably, the recombinant lysosomal
enzyme has increased affinity for the target cell, in comparison
with the corresponding affinity of a naturally occurring lysosomal
enzyme for the target cell. In a specific embodiment, the target
cell at the target site may be a Kupffer cell in the liver of the
subject.
[0169] In a preferred embodiment, the recombinant lysosomal enzyme
may be selected from the group consisting of glucocerebrosidase
(GCD), acid sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase or sialidase.
[0170] Most preferably, this recombinant lysosomal enzyme is
glucocerebrosidase (GCD).
[0171] In a third aspect, the invention relates to a method of
producing a high mannose protein. Accordingly, the method of the
invention comprises the steps of: (a) preparing a culture of
recombinant host cells transformed or transfected with a
recombinant nucleic acid molecules encoding for a recombinant
protein of interest or with an expression vector comprising the
recombinant nucleic acid molecules; (b) culturing the host cell
culture prepared by step (a) in suspension under conditions
permitting the expression of the high mannose protein, wherein the
host cells produce the protein in a highly mannosylated form; (c)
harvesting the cells from the culture provided in (a) and
recovering the protein from the cells; and (d) purifying the
protein of step (c) by a suitable protein purification method.
[0172] Optionally and preferably, the recombinant protein may be
produced by plant cells according to the present invention by
culturing in a device described with regard to U.S. Pat. No.
6,391,638, issued on May 21, 2002 and hereby incorporated by
reference as if fully set forth herein. Conditions for culturing
plant cells in suspension with this device are described with
regard to the US patent application entitled "CELL/TISSUE CULTURING
DEVICE, SYSTEM AND METHOD" by one of the present inventors and
owned in common with the present application, which is hereby
incorporated by reference as if fully set forth herein and which
was filed on the same day as the present application.
[0173] A particular and non limiting example for recovering and
purification of a high mannose protein of interest produced by the
method of the invention may be found in the following Examples. The
Examples show that a recombinant h-GCD produced by the invention
was unexpectedly bound to internal membrane of the transformed
carrot cells of the invention and not secreted to the medium. The
soluble rh-GCD may be separated from cell debris and other
insoluble component according to means known in the art such as
filtration or precipitation. For Example, following a freeze-thaw
cycle, the cells undergo breakage and release of intracellular
soluble proteins, whereas the h-GCD remains bound to insoluble
membrane debris. This soluble and insoluble membrane debris mixture
was next centrifuged and the soluble fraction was removed thus
simplifying the purification. The membrane bound h-GCD can then be
dissolved by mechanical disruption in the presence of a mild
detergent, protease inhibitors and neutralizing oxidation reagent.
The soluble enzyme may be further purified using chromatography
techniques, such as cation exchange and hydrophobic interaction
chromatography columns During rh-GCD production in the bio-reactor
and the purification process the h-GCD identity, yield, purity and
enzyme activity can be determined by one or more biochemical
assays. Including but not limited to detecting hydrolysis of the
enzyme's substrate or a substrate analogue, SDS-polyacrylamide gel
electrophoresis analysis and immunological analyses such as ELISA
and Western blot.
[0174] According to a preferred embodiment, the host cell used by
this method comprises the host cell of the invention.
[0175] In another preferred embodiment, the high mannose protein
produced by the method of the invention may be a biologically
active high mannose lysosomal enzyme having at least one
oligosaccharide chain comprising an exposed mannose residue.
[0176] This recombinant enzyme can bind to a mannose receptor on a
target cell in a target site. More particularly, the recombinant
enzyme produced by the method of the invention has increased
affinity for the target cell, in comparison with the corresponding
affinity of a naturally occurring lysosomal enzyme to the target
cell. Accordingly, the target cell at the target site may be
Kupffer cell in the liver of the subject.
[0177] In a specific embodiment, this lysosomal enzyme may be
selected from the group consisting of glucocerebrosidase (GCD),
acid sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase and sialidase. Most
preferably, this lysosomal enzyme may be glucocerebrosidase
(GCD).
[0178] In another preferred embodiment, the host cell used by the
method of the invention may be a plant root cell selected from the
group consisting of Agrobacterium rihzogenes transformed root cell,
celery cell, ginger cell, horseradish cell and carrot cell. Most
preferably, the plant root cell is a carrot cell. It should be
particularly noted that the transformed host carrot cells are grown
in suspension.
[0179] In a further aspect, the present invention relates to a
method for treating a subject, preferably a mammalian subject,
having lysosomal storage disease by using exogenous recombinant
lysosomal enzyme.
[0180] Disclosed and described, it is to be understood that this
invention is not limited to the particular examples, process steps,
and materials disclosed herein as such process steps and materials
may vary somewhat. It is also to be understood that the terminology
used herein is used for the purpose of describing particular
embodiments only and not intended to be limiting since the scope of
the present invention will be limited only by the appended claims
and equivalents thereof.
[0181] Throughout this specification and the claims which follow,
unless the context requires otherwise, the word "comprise", and
variations such as "comprises" and "comprising", will be understood
to imply the inclusion of a stated integer or step or group of
integers or steps but not the exclusion of any other integer or
step or group of integers or steps.
[0182] It must be noted that, as used in this specification and the
appended claims, the singular forms "a", "an" and "the" include
plural referents unless the content clearly dictates otherwise.
[0183] The following examples are representative of techniques
employed by the inventors in carrying out aspects of the present
invention. It should be appreciated that while these techniques are
exemplary of preferred embodiments for the practice of the
invention, those of skill in the art, in light of the present
disclosure, will recognize that numerous modifications can be made
without departing from the spirit and intended scope of the
invention.
EXAMPLES
Experimental Procedures
[0184] Plasmid vectors [0185] CE-T--Was constructed from plasmid CE
obtained from Prof. Galili [U.S. Pat. No. 5,367,110 November 22,
(1994)].
[0186] Plasmid CE was digested with SalI.
[0187] The SalI cohesive end was made blunt-ended using the large
fragment of DNA polymerase I. Then the plasmid was digested with
PstI and ligated to a DNA fragment coding for the ER targeting
signal from the basic endochitinase gene [Arabidopsis thaliana]
ATGAAGACTAATCTTTTTCTCTTTCTCATCTTTTCA
CTTCTCCTATCATTATCCTCGGCCGAATTC, and vacuolar targeting signal from
Tobacco chitinase A: GATCTTTTAGTCGATACTATG digested with SmaI and
PstI. [0188] pGREENII--obtained from Dr. P. Mullineaux [Roger P.
Hellens et al., (2000)
[0189] Plant Mol. Bio. 42:819-832]. Expression from the pGREEN II
vector is controlled by the .sup.35S promoter from Cauliflower
Mosaic Virus, the TMV (Tobacco Mosaic Virus) omega translational
enhancer element and the octopine synthase terminator sequence from
Agrobacterium tumefaciens.
[0190] cDNA
[0191] hGCD--obtained from ATCC (Accession No. 65696), GC-2.2
[GCS-2 kb; lambda-EZZ-gamma3 Homo sapiens] containing glucosidase
beta acid [glucocerebrosidase]. Insert lengths (kb): 2.20; Tissue:
fibroblast WI-38 cell.
Construction of Expression Plasmid
[0192] The cDNA coding for hGCD (ATTC clone number 65696) was
amplified using the forward: 5' CAGAATTCGCCCGCCCCTGCA 3' and the
reverse: 5' CTCAGATCTTGGCGATGCCACA 3' primers. The purified PCR DNA
product was digested with endonucleases EcoRI and BglII (see
recognition sequences underlined in the primers) and ligated into
an intermediate vector having an expression cassette E-T digested
with the same enzymes. The expression cassette was cut and eluted
from the intermediate vector and ligated into the binary vector
pGREENII using restriction enzymes SmaI and XbaI, forming the final
expression vector. Kanamycine resistance is conferred by the NPTII
gene driven by the nos promoter obtained together with the pGREEN
vector (FIG. 1B). The resulting expression cassette is presented by
FIG. 1A.
[0193] The resulting plasmid was sequenced to ensure correct
in-frame fusion of the signals using the following sequencing
primers: 5' 35S promoter: 5' CTCAGAAGACCAGAGGGC 3', and the 3'
terminator: 5' CAAAGCGGCCATCGTGC 3'.
Establishment of Carrot Callus and Cell Suspension Cultures
[0194] Establishment of carrot callus and cell suspension cultures
we preformed as described previously by Tones K. C. (Tissue culture
techniques for horticular crops, p.p. 111, 169).
Transformation of Carrot Cells and Isolation of Transformed
Cells.
[0195] Transformation of carrot cells was performed using
Agrobacterium transformation by an adaptation of a method described
previously [Wurtele, E. S. and Bulka, K. Plant Sci. 61:253-262
(1989)]. Cells growing in liquid media were used throughout the
process instead of calli. Incubation and growth times were adapted
for transformation of cells in liquid culture. Briefly,
Agrobacteria were transformed with the pGREEN II vector by
electroporation [den Dulk-Ra, A. and Hooykaas, P. J. (1995) Methods
Mol. Biol. 55:63-72] and then selected using 30 mg/ml paromomycine
antibiotic. Carrot cells were transformed with Agrobacteria and
selected using 60 mg/ml of paromomycine antibiotics in liquid
media.
Screening of Transformed Carrot Cells for Isolation of Calli
Expressing High Levels of GCD
[0196] 14 days following transformation, cells from culture were
plated on solid media at dilution of 3% packed cell volume for the
formation of calli from individual clusters of cells. When
individual calli reached 1-2 cm in diameter, the cells were
homogenized in SDS sample buffer and the resulting protein extracts
were separated on SDS-PAGE [Laemmli U., (1970) Nature 227:680-685]
and transferred to nitrocellulose membrane (hybond C
nitrocellulose, 0.45 micron. Catalog No: RPN203C From Amersham Life
Science). Western blot for detection of GCD was performed using
polyclonal anti hGCD antibodies (described herein below). Calli
expressing significant levels of GCD were expanded and transferred
to growth in liquid media for scale up, protein purification and
analysis.
Preparation of Polyclonal Antibodies
[0197] 75 micrograms recombinant GCD (Cerezyme.TM.) were suspended
in 3 ml complete Freund's adjuvant and injected to each of two
rabbits. Each rabbit was given a booster injection after two weeks.
The rabbits were bled about 10 days after the booster injection and
again at one week intervals until the antibody titer began to drop.
After removal of the clot the serum was divided into aliquots and
stored at -20.degree. C.
Upscale Culture Growth in a Bioreactor
[0198] An about 1 cm (in diameter) callus of genetically modified
carrot cells containing the rh-GCD gene was plated onto Murashige
and Skoog (MS) 9 cm diameter agar medium plate containing 4.4 gr/1
MSD medium (Duchefa), 9.9 mg/l thiamin HCl (Duchefa), 0.5 mg folic
acid (Sigma) 0.5 mg/l biotin (Duchefa), 0.8 g/l Casein hydrolisate
(Ducifa), sugar 30 g/l and hormones 2-4 D (Sigma). The callus was
grown for 14 days at 25.degree. C.
[0199] Suspension cell culture was prepared by sub-culturing the
transformed callus in a MSD liquid medium (Murashige & Skoog
(1962) containing 0.2 mg/l 2,4-dichloroacetic acid), as is well
known in the art. The suspension cells were cultivated in 250 ml
Erlenmeyer flask (working volume starts with 25 ml and after 7 days
increases to 50 ml) at 25.degree. C. with shaking speed of 60 rpm.
Subsequently, cell culture volume was increased to 1 L Erlenmeyer
by addition of working volume up to 300 ml under the same
conditions. Inoculum of the small bio-reactor (10 L) [see
WO98/13469] containing 4 L MSD medium, was obtained by addition of
400 ml suspension cells derived from two 1 L Erlenmeyer that were
cultivated for seven days. After week of cultivation at 25.degree.
C. with 1 Lpm airflow, MDS medium was added up to 10 L and the
cultivation continued under the same conditions. After additional
five days of cultivation, most of the cells were harvested and
collected by passing the cell media through 80.mu. net. The extra
medium was squeezed out and the packed cell cake was store at
-70.degree. C.
[0200] Further details of the bioreactor device may be found with
regard to U.S. Pat. No. 6,391,638, issued on May 21, 2002 and
previously incorporated by reference.
Protein Purification
[0201] In order to separate the medium from the insoluble GCD,
frozen cell cake containing about 100 g wet weight cells was
thawed, followed by centrifugation of the thawed cells at
17000.times.g for 20 min at 4.degree. C. The insoluble materials
and intact cells were washed by re-suspension in 100 ml washing
buffer (20 mM sodium phosphate pH 7.2, 20 mM EDTA), and then
precipitated by centrifugation at 17000 g for 20 min at 4.degree.
C. The rh-GCD (recombinant human GCD) was extracted and solubilized
by homogenization of the pellet in 200 ml extraction buffer (20 mM
sodium phosphate pH 7.2, 20 mM EDTA, 1 mM PMSF, 20 mM ascorbic
acid, 3.8 g polyvinylpolypyrrolidone (PVPP), 1 mM DTT and 1%
Triton-x-100). The homogenate was then shaken for 30 min at room
temperature and clarified by centrifugation at 17000.times.g for 20
min at 4.degree. C. The pellet was discarded and the pH of the
supernatant was adjusted to pH 5.5 by addition of concentrated
citric acid. Turbidity generated after pH adjustment was clarified
by centrifugation under the same conditions described above.
[0202] Further purification was performed by chromatography columns
procedure as follows: 200 ml of clarified medium were loaded on 20
ml strong cation exchange resin (Macro-Prep high-S support,
Bio-Rad) equilibrated in 25 mM sodium citrate buffer pH 5.5, packed
in a XK column (2.6.times.20 cm). The column was integrated with an
AKTA (prime system (Amersham Pharmacia Biotech) that allowed to
monitor the conductivity, pH and absorbency at 280 nm. The sample
was loaded at 20 ml/min, afterwards the column was washed with
equilibration buffer (25 mM sodium citrate buffer pH 5.5) at flow
rate of 12 ml/min until UV absorbency reached the base line.
Pre-elution of the rh-GCD was performed with equilibration buffer
containing 200 mM NaCl and the elution was obtained with
equilibration buffer containing 600 mM NaCl. Fractions collected
during the run were monitored by enzyme activity assay, and tubes
exhibiting enzymatic activity (in the elution peak) were pooled.
Pooled samples were diluted (1:5) in water containing 5% ethanol
and pH adjusted to 6.0 with NaOH. Sample containing the rh-GCD was
applied on the second XK column (1.6.times.20 cm) packed with 10 ml
of the same resin as in the previous column. The resin in this
column was equilibrate with 20 mM citrate buffer pH 6.0 containing
5% ethanol. Following the sample load the column was washed with
the equilibration buffer and the GCD was eluted from the column by
elution buffer (20 mM citrate buffer pH 6.0, 5% ethanol and 1M
NaCl). The fractions of the absorbent peak in the elution step were
pooled and applied on a third column.
[0203] The final purification step was performed on a XK column
(1.6.times.20 cm) packed with 8 ml hydrophobic interaction resin
(TSK gel, Toyopearl Phenyl-650C, Tosoh Corp.). The resin was
equilibrated in 10 mM citrate buffer pH 6.0 containing 5% ethanol.
The GCD elution pool from the previous column was loaded at 6
ml/min followed by washing with equilibration buffer until the UV
absorbent reach the baseline. The pure GCD was eluted by 10 mM
citric buffer containing 50% ethanol, pooled and stored at
-20.degree. C.
Determination of Protein Concentration
[0204] Protein concentrations in cell extracts and fractions were
assayed by the method of Lowry/Bradford (Bio Rad protein assay)
[Bradford, M., Anal. Biochem. (1976) 72:248] using a bovine serum
albumin standard (fraction V Sigma). Alternatively, concentration
of homogenous protein samples was determined by absorption at 280
nm, 1 mg/ml=1.4 O.D.sub.280. Purity was determined by 280/260 nm
ratio.
GCD Enzyme Activity Assay
[0205] Enzymatic activity of GCD was determined using
p-nitrophenyl-.beta.-D-glucopyranoside (Sigma) as a substrate.
Assay buffer contained 60 mM phosphate-citrate buffer pH=6, 4 mM
.beta.-mercaptoethanol, 1.3 mM EDTA, 0.15% Triton X-100, 0.125%
sodium taurocholate. Assay was preformed in 96 well ELISA plates,
0-50 microliter of sample were incubated with 250 microliter assay
buffer and substrate was added to final concentration of 4 mM. The
reaction was incubated at 37.degree. C. for 60 min. Product
(p-nitrophenyl; pNP) formation was detected by absorbance at 405 nm
Absorbance at 405 nm was monitored at t=0 and at the end point.
After 60 min, 6 microliter of 5N NaOH were added to each well and
absorbance at 405 nm was monitored again. Reference standard curve
assayed in parallel, was used to quantitate concentrations of GCD
in the tested samples [Friedman et al., (1999) Blood,
93(9):2807-16].
[0206] Kinetic Studies:
[0207] For kinetic studies, GCD activity was assayed as described
by hereinabove with some modifications, using a fluorescent
short-acyl-chain analogue of glucosylceramide,
N-[6-[(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino]hexanoyl]-D
erythro-glucosylsphingosine (C6-NBD-D-erythro-GlcCer).
C.sub.6-NBD-GlcCer was synthesized by N-acylation of
glucosylsphingosine using succinimidyl
6-7-nitrobenzo-2-oxa-1,3-diazol-4-yl) aminohexanoate as described
by Schwarzmann and Sandhoff (1987). The assay was performed using
0.2 ng of either Cerezyme.RTM. or plant GCD of the invention in a
final volume of 200 n1 MES buffer (50 mM, pH 5.5). Concentrations
of C.sub.6-NBD-GlcCer ranged from 0.25 to 100 .mu.M. Reactions were
allowed to proceed for 5 min at 37.degree. C., and were stopped by
addition of 1.5 ml of chloroform/methanol (1:2, v/v) prior to
extraction and analysis of the fluorescent lipids.
[0208] Biochemical Analyses:
[0209] In Gel Proteolysis and Mass Spectrometry Analysis
[0210] The stained protein bands in the gel were cut with a clean
razor blade and the proteins in the gel were reduced with 10 mM DTT
and modified with 100 mM iodoacetamide in 10 mM ammonium
bicarbonate. The gel pieces were treated with 50% acetonitrile in
10 mM ammonium bicarbonate to remove the stain from the proteins
following by drying the gel pieces. The dried gel pieces were
rehydrated with 10% acetonitrile in 10 mM ammonium bicarbonate
containing about 0.1 .mu.g trypsin per sample. The gel pieces were
incubated overnight at 37.degree. C. and the resulting peptides
were recovered with 60% acetonitrile with 0.1%
trifluoroacetate.
[0211] The tryptic peptides were resolved by reverse-phase
chromatography on 0.1.times.300-mm fused silica capillaries
(J&W, 100 micrometer ID) home-filled with porous R2
(Persepective). The peptides were eluted using a 80-min linear
gradient of 5 to 95% acetonitrile with 0.1% acetic acid in water at
flow rate of about 1 .mu.l/min. The liquid from the column was
electrosprayed into an ion-trap mass spectrometer (LCQ, Finnegan,
San Jose, Calif.). Mass spectrometry was performed in the positive
ion mode using repetitively full MS scan followed by collision
induces dissociation (CID) of the most dominant ion selected from
the first MS scan. The mass spectrometry data was compared to
simulated proteolysis and CID of the proteins in the NR-NCBI
database using the Sequest software [J. Eng and J. Yates,
University of Washington and Finnegan, San Jose].
[0212] The amino terminal of the protein was sequenced on Peptide
Sequencer 494A (Perkin Elmer) according to manufacture
instructions.
GCD Uptake of Peritoneal Macrophages
[0213] Targeting and uptake of GCD to macrophages is known to be
mediated by the Mannose/N-acetylglucosmine receptor and can be
determined using thioglycolate-elicited peritoneal macrophages
obtained from mice, as described by Stahl P. and Gordon S. [J. Cell
Biol. (1982) 93(1):49-56]. Briefly, mice (female, strain C57-B6)
were injected intraperitoneally with 2.5 ml of 2.4%
Bacto-thioglycolate medium w/o dextrose (Difco Cat. No. 0363-17-2).
After 4-5 days, treated mice were sacrificed by cervical
dislocation and the peritoneal cavity rinsed with phosphate
buffered saline. Cells were pelleted by centrifugation
(1000.times.g 10 min) and were resuspended in DMEM (Beit Haemek,
Israel) containing 10% fetal calf serum. Cells were then plated at
1-2.times.10.sup.5 cell/well in 96-well tissue culture plates and
incubated at 37.degree. C. After 90 minutes, non-adherent cells
were washed out three times using PBS, and the adherent macrophages
were incubated for 90 min at 37.degree. C., in culture medium
containing specified quantities of rhGCD, ranging from 0 to 40
micrograms in 200 microliter final volume, in the absence and
presence of yeast mannan (2-10, 5 mg/ml). After incubation, medium
containing excess rGCD was removed, and cells were washed three
times with PBS and then lysed with lysis buffer (10 mM Tris pH=7.3,
1 mM MgCl.sub.2, 0.5% NP-40 and protease inhibitors). The activity
of rGCD taken up by the cells was determined by subjecting the cell
lysates to in vitro glycosidase assay as described above.
Example 1
Construction of Expression Plasmid
[0214] This Example describes the construction of an exemplary
expression plasmid, used with regard to the Examples below, in more
detail.
[0215] The cDNA coding for hGCD (ATTC clone number 65696) was
amplified using the forward: 5' CAGAATTCGCCCGCCCCTGCA 3' (also
denoted by SEQ ID NO: 3) and the reverse: 5' CTCAGATCTTGGCGATGCCACA
3' (also denoted by SEQ ID NO: 4) primers.
[0216] The purified PCR DNA product was digested with endonucleases
EcoRI and BglII (see recognition sequences underlined in the
primers) and ligated into an intermediate vector having an
expression cassette CE-T digested with the same enzymes. CE-T
includes ER targeting signal MKTNLFLFLIFSLLLSLSSAEF (also denoted
by SEQ ID NO: 1) from the basic endochitinase gene [Arabidopsis
thaliana], and vacuolar targeting signal from Tobacco chitinase A:
DLLVDTM* (also denoted by SEQ ID NO: 2).
[0217] The expression cassette was cut and eluted from the
intermediate vector and ligated into the binary vector pGREENII
using restriction enzymes SmaI and XbaI, forming the final
expression vector. Kanamycine resistance is conferred by the NPTII
gene driven by the nos promoter together with the pGREEN vector
(FIG. 1B). The resulting expression cassette is presented by FIG.
1A.
[0218] The resulting plasmid was sequenced to ensure correct
in-frame fusion of the signals using the following sequencing
primers:
[0219] Primer from the 5' 35S promoter: 5' CTCAGAAGACCAGAGGGC 3'
(also denoted by SEQ ID NO: 5), and the 3' terminator: 5'
CAAAGCGGCCATCGTGC 3' (also denoted by SEQ ID NO: 6). The verified
cloned hGCD coding sequence is denoted by SEQ ID NO: 7.
Example 2
Transformation of Carrot Cells and Screening for Transformed Cells
Expressing rhGCD
[0220] This Example describes an exemplary method for transforming
carrot cells according to the present invention, as used in the
Examples below.
[0221] Transformation of carrot cells was performed by
Agrobacterium transformation as described previously by [Wurtele
and Bulka (1989) ibid.]. Genetically modified carrot cells were
plated onto Murashige and Skoog (MS) agar medium with antibiotics
for selection of transformants. As shown by FIG. 2, extracts
prepared from arising calli were tested for expression of GCD by
Western blot analysis using anti hGCD antibody, and were compared
to Cerezyme standard (positive control) and extracts of
non-transformed cells (negative control). Of the various calli
tested, one callus (number 22) was selected for scale-up growth and
protein purification.
[0222] The Western blot was performed as follows:
[0223] For this assay, proteins from the obtained sample were
separated in SDS polyacrylamide gel electrophoresis and transferred
to nitrocellulose. For this purpose, SDS polyacrylamide gels were
prepared as follows. The SDS gels consist of a stacking gel and a
resolving gel (in accordance with Laemmli, UK 1970, Cleavage of
structural proteins during assembly of the head of bacteriophage
T4, Nature 227, 680-685). The composition of the resolving gels was
as follows: 12% acrylamide (Bio-Rad), 4 microliters of TEMED
(N,N,N',N'-tetramethylethylenediamine; Sigma catalog number T9281)
per 10 ml of gel solution, 0.1% SDS, 375 mM Tris-HCl, pH 8.8 and
ammonium persulfate (APS), 0.1%. TEMED and ammonium persulfate were
used in this context as free radical starters for the
polymerization. About 20 minutes after the initiation of
polymerization, the stacking gel (3% acrylamide, 0.1% SDS, 126 mM
Tris-HCl, pH 6.8, 0.1% APS and 5 microliters of TEMED per 5 ml of
stacking gel solution) was poured above the resolving gel, and a 12
or 18 space comb was inserted to create the wells for samples.
[0224] The anode and cathode chambers were filled with identical
buffer solution: Tris glycine buffer containing SDS (Biorad,
catalog number 161-0772), pH 8.3. The antigen-containing material
was treated with 0.5 volume of sample loading buffer (30 ml
glycerol (Sigma catalog number G9012), 9% SDS, 15 ml
mercaptoethanol (Sigma catalog number M6250), 187.5 mM Tris-HCl, pH
6.8, 500 microliters bromophenol blue, all volumes per 100 ml
sample buffer), and the mixture was then heated at 100.degree. C.
for 5 minutes and loaded onto the stacking gel.
[0225] The electrophoresis was performed at room temperature for a
suitable time period, for example 45-60 minutes using a constant
current strength of 50-70 volts followed by 45-60 min at 180-200
Volt for gels of 13 by 9 cm in size. The antigens were then
transferred to nitrocellulose (Schleicher and Schuell, Dassel).
[0226] Protein transfer was performed substantially as described
herein. The gel was located, together with the adjacent
nitrocellulose, between Whatmann 3 MM filter paper, conductive, 0.5
cm-thick foamed material and wire electrodes which conduct the
current by way of platinum electrodes. The filter paper, the foamed
material and the nitrocellulose were soaked thoroughly with
transfer buffer (TG buffer from Biorad, catalog number 161-0771,
diluted 10 times with methanol and water buffer (20% methanol)).
The transfer was performed at 100 volts for 90 minutes at 4.degree.
C.
[0227] After the transfer, free binding sites on the nitrocellulose
were saturated, at 4.degree. C. over-night with blocking buffer
containing 1% dry milk (Dairy America), and 0.1% Tween 20 (Sigma
Cat P1379) diluted with phosphate buffer (Riedel deHaen, catalog
number 30435). The blot strips were incubated with an antibody
(dilution, 1:6500 in phosphate buffer containing 1% dry milk and
0.1% Tween 20 as above, pH 7.5) at 37.degree. C. for 1 hour.
[0228] After incubation with the antibody, the blot was washed
three times for in each case 10 minutes with PBS (phosphate
buffered sodium phosphate buffer (Riedel deHaen, catalog number
30435)). The blot strips were then incubated, at room temperature
for 1 h, with a suitable secondary antibody (Goat anti rabbit
(whole molecule) HRP (Sigma cat #A-4914)), dilution 1:3000 in
buffer containing 1% dry milk (Dairy America), and 0.1% Tween 20
(Sigma Cat P1379) diluted with phosphate buffer (Riedel deHaen,
catalog number 30435)). After having been washed several times with
PBS, the blot strips were stained with ECL developer reagents
(Amersham RPN 2209).
[0229] After immersing the blots in the ECL reagents the blots were
exposed to X-ray film FUJI Super RX 18.times.24, and developed with
FUJI-ANATOMIX developer and fixer (FUJI-X fix cat# FIXRTU 1 out of
2). The bands featuring proteins that were bound by the antibody
became visible after this treatment.
[0230] Upscale Culture Growth in Bioreactors
[0231] Suspension cultures of callus 22 were obtained by
sub-culturing of transformed callus in a liquid medium. Cells were
cultivated in shaking Erlenmeyer flasks, until total volume was
sufficient for inoculating the bioreactor (as described in
Experimental procedures). The genetically modified transgenic
carrot cells can be cultivated over months, and cell harvest can be
obtained in cycling of 5 to 7 days (data not shown). At the seventh
cultivation day, when the amount of rh-GCD production in carrot
cell is at the peak, cells were harvested by passing of culture
through 100 mesh nets. It should be noted that cells may be
harvested by means known in the art such as filtration or
centrifugation. The packed cell cake, which provides the material
for purification of h-GCD to homogeneity, can be stored at freezing
temperature.
Example 3
Purification of Recombinant Active hGCD Protein from Transformed
Carrot Cells
[0232] Recombinant h-GCD expressed in transformed carrot cells was
found to be bound to internal membranes of the cells and not
secreted to the medium. Mechanically cell disruption leaves the
rGCD bound to insoluble membrane debris (data not shown). rGCD was
then dissolved using mild detergents, and separated from cell
debris and other insoluble components. The soluble enzyme was
further purified using chromatography techniques, including cation
exchange and hydrophobic interaction chromatography columns as
described in Experimental procedures.
[0233] In order to separate the medium from the insoluble GCD,
frozen cell cake containing about 100 g wet weight cells was
thawed, followed by centrifugation at 17000.times.g for 20 min at
4.degree. C. The insoluble materials and intact cells were washed
by re-suspension in 100 ml washing buffer (20 mM sodium phosphate
pH 7.2, 20 mM EDTA), and precipitated by centrifugation at 17000 g
for 20 min at 4.degree. C. The rGCD was extracted and solubilized
by homogenization of the pellet in 200 ml extraction buffer (20 mM
sodium phosphate pH 7.2, 20 mM EDTA, 1 mM PMSF, 20 mM ascorbic
acid, 3.8 g polyvinylpolypyrrolidone (PVPP), 1 mM DTT, 1%
Triton-x-100 (Sigma)). The homogenate was shaken for 30 min at room
temperature and clarified by centrifugation at 17000 g for 20 min
at 4.degree. C. The pellet was discarded and the pH of the
supernatant was adjusted to pH 5.5 by addition of concentrated
citric acid. Turbidity generated after pH adjustment was clarified
by centrifugation under the same conditions described above.
[0234] Further purification was performed by chromatography columns
as follows: in a first stage, 200 ml of clarified extract were
loaded on 20 ml strong cation exchange resin (Macro-Prep high-S
support, Bio-Rad) equilibrated in 25 mM sodium citrate buffer pH
5.5, packed in a XK column (2.6.times.20 cm). The column was
integrated with an AKTA prime system (Amersham Pharmacia Biotech)
that allowed to monitor the conductivity, pH and absorbency at 280
nm. The sample was loaded at 20 ml/min, afterwards the column was
washed with equilibration buffer (25 mM sodium citrate buffer pH
5.5) at flow rate of 12 ml/min until UV absorbency reached the base
line. Pre-elution of the rh-GCD was performed with equilibration
buffer containing 200 mM NaCl and the elution was obtained with
equilibration buffer containing 600 mM NaCl. Fractions collected
during the run were monitored by enzyme activity assay, and tubes
exhibiting enzymatic activity (in the elution peak) were pooled.
Pooled samples were diluted (1:5) in water containing 5% ethanol
and pH adjusted to 6.0 with NaOH.
[0235] FIG. 3A represents a standard run of this purification
stage. The fractions collected during the run were monitored by
enzyme activity assay, as shown by FIG. 3B, and FIG. 3C shows
coomassie-blue stain of elution fractions assayed for activity.
[0236] Elution fractions containing the rGCD were applied on a
second XK column (1.6.times.20 cm) packed with 10 ml of the same
resin as in the previous column, for a second purification stage.
The resin in this column was equilibrated with 20 mM citrate buffer
pH 6.0 containing 5% ethanol. Following the sample load the column
was washed with the equilibration buffer and the rGCD was eluted
from the column by elution buffer (20 mM citrate buffer pH 6.0, 5%
ethanol and 1M NaCl). FIG. 3D represents a standard run of this
purification stage. The fractions collected during the run were
monitored by enzyme activity assay, as shown by FIG. 3E, and FIG.
3F shows a coomassie-blue stain of elution fractions assayed for
activity.
[0237] The fractions of the absorbent peak in the elution step were
pooled and applied on a third column, for a third purification
stage. The third purification stage was performed on a XK column
(1.6.times.20 cm) packed with 8 ml hydrophobic interaction resin
(TSK gel, Toyopearl Phenyl-650C, Tosoh Corp.). The resin was
equilibrated in 10 mM citrate buffer pH 6.0 containing 5% ethanol.
The GCD elution pool from the previous column was loaded at 6
ml/min followed by washing with equilibration buffer until the UV
absorbance reached the baseline. The pure GCD was eluted by 10 mM
citric buffer containing 50% ethanol, pooled and stored at
-20.degree. C.
[0238] FIG. 4A represents a standard run of this purification
stage. The fractions collected during the run were monitored by
enzyme activity assay (FIG. 4B), and FIG. 4C shows coomassie-blue
stain of elution fractions assayed for activity.
[0239] In a batch purification of cells that were processed, rGCD
protein was purified to a level greater than 95%; if only the first
and third stages are performed, purity is achieved at a level of
about 80% (results not shown).
[0240] Biochemical Analysis
[0241] To validate the identity of purified rhGCD, Mass-Spec
Mass-Spec (MSMS) analysis was preformed. Results obtained showed
49% coverage of protein sequence that matched the predicted amino
acid sequence, based on the DNA of the expression cassette,
including the leader peptide and targeting sequences.
[0242] Characterization and Sequencing of prGCD:
[0243] To further characterize the plant produced human recombinant
GCD of the invention, the rhGCD was solubilized using Triton X-100,
in the presence of an antioxidant, and purified to homogeneity by
cation exchange and hydrophobic chromatography (FIG. 9a).
Amino-acid sequencing of the plant produced human recombinant GCD
of the invention demonstrated that the rhGCD sequence (SEQ ID NO:
15) corresponds to that of the human GCD (Swiss Prot P04062,
protein ID AAA35873), and includes two additional amino acids (EF)
at the N-terminus (designated -2 and -1 accordingly), derived from
the linker used for fusion of the signal peptide, and an additional
7 amino acids at the C-terminus (designated 497-503) derived from
the vacuolar targeting signal.
[0244] Immunodetection of the purified plant produced human
recombinant GCD of the invention with anti-GCD polyclonal antibody
was performed by Western blotting of the SDS-PAGE separated
protein, along with Cerezyme.RTM. protein (FIG. 9b), confirming
antigenic identity of the plant produced and CHO-produced
proteins.
[0245] Enzymatic Activity of Recombinant hGCD:
[0246] The activity of plant produced human recombinant GCD of the
present invention was compared to that of Cerezyme.RTM., using a
fluorescent GlcCer analogue. FIG. 12 shows that similar specific
activities were obtained, with V.sub.max values of 0.47.+-.0.08
Kmol C6-NBD-ceramide formed/min/mg protein for prGCD and
0.43.+-.0.06 for Cerezyme.RTM., and similar K.sub.m values
(20.7.+-.0.7 KM for the GCD of the invention and 15.2.+-.4.8 KM for
Cerezyme.RTM.). Thus, these kinetic studies show that the activity
of the plant produced human recombinant GCD of the present
invention is similar to that of the CHO expressed enzyme.
[0247] Uptake and Activity of Recombinant hGCD in Peritoneal
Macrophages
[0248] To determine whether the rhGCD produced in carrot has been
correctly glycosylated and can undergo uptake by target cells, and
thus be useful for treatment of Gaucher's disease, the ability of
the rhGCD to bind to and be taken up by macrophages was next
assayed. Targeting of rhGCD to macrophages is mediated by the
Mannose/N-acetylglucosamine (Man/GlcNAc) receptor and can be
determined using thioglycolate-elicited peritoneal macrophages. As
shown by FIG. 5, rGCD undergoes uptake by cells at a high level.
FIG. 5A shows uptake by cells of rGCD according to the present
invention with regard to mannan concentration.
[0249] FIG. 5A shows uptake at comparable levels with Cerezyme.TM.
(this preparation was prepared to 80% purity with only the first
and third stages of the purification process described above).
[0250] FIGS. 5B and 5C show that rGCD uptake is at a higher level
than Cerezyme.TM., as this preparation was prepared to greater than
95% purity with all three stages of the purification process
described above.
[0251] With regard to FIG. 5C, clearly the percent of specific
activity from total activity, inhibited by 4 mg/ml mannan, is
higher for the GCD of the present invention (rGCD or recombinant
human GCD) than for the currently available product in the market
as follows: GCD (CB-mixl, which is the rGCD of the present
invention)--75% Cerezyme--65%. Furthermore, as shown by the
figures, addition of mannan clearly inhibited binding of rGCD by
the cells. At concentration of 2 mg/ml of mannan, the binding of
rGCD was inhibited by 50%.
[0252] These results show that even without remodeling of glycan
structures, rhGCD expressed and purified from transformed carrot
cells can undergo uptake to target macrophage cells specifically
through Man/GlcNAc receptors. Moreover, this recombinant rhGCD is
enzymatically active.
[0253] FIG. 5D shows that the rhGCD is also recognized by an
anti-GCD antibody in a Western blot; rGCD refers to the protein
according to the present invention, while GCD standard (shown at 5,
10 and 25 ng per lane) is commercially purchased GCD
(Cerezyme.RTM.).
Example 4
Toxicology Testing
[0254] The material obtained according to the above purification
procedure was tested according to standard toxicology testing
protocols (Guidance for Industry on Single Dose Acute Toxicity
Testing for Pharmaceuticals, Center for Drug Evaluation and
Research (CDER) PT 1 (61 FR 43934, Aug. 26, 1996) and by ICH M3(M)
Non-clinical Safety Studies for the Conduct of Human Clinical
Trials for Pharmaceuticals CPMP/ICH/286/95 modification, Nov. 16,
2000).
[0255] Mice were injected as follows: An initial dose of 1.8 mg/kg
(clinical dose) was followed by doses of 9 and 18 mg/kg. Testing
groups included six mice (ICR CD-1; 3 males and 3 females) for
receiving rGCD (in a liquid carrier featuring 25 mM citrate buffer,
150 mM NaCl, 0.01% Tween 80, 5% ethanol) according to the present
invention, and another six mice for being treated with the carrier
alone as a control group. The mice were then observed for 14 days
and were euthanized.
[0256] In another study, vehicle solution alone, or doses of prGCD
in multiples of 1, 5, or 10 times the standard clinical dose (60
units/kg) were given to ICR (CD-1.RTM.) mice. The animals (6 per
group, 3 males and 3 females), received the drug intravenously in a
10 ml/kg volume.
[0257] Both toxicity studies revealed no obvious treatment-related
adverse reactions, no gross pathological findings, no changes in
body weight and no mortality incidences observed even at the
highest dose administered. Furthermore, blood samples taken from
animals in the high-dose group, which had been administered with
10-fold the clinical dose, were tested for hematology and clinical
chemistry. All hematology and clinical chemistry values were in
normal ranges. In addition, the animals treated with the high dose
were subjected to histopathological examination of the liver,
spleen and kidney, and there were no macro or micro
histopathological findings.
Example 5
Glycosylation Analysis
[0258] Analysis of glycan structures present on rGCD produced as
described with regard to the previous Examples was performed. As
described in greater detail below, results indicate that the
majority of glycans contain terminal mannose residues as well as
high mannose structures. Advantageously, this high mannose product
was found to be biologically active, and therefore no further steps
were needed for its activation.
[0259] The following methods were used to determine the
glycosylation structure of the recombinant hGCD produced according
to the Examples given above. Briefly, the monosaccharide linkages
for both N- and O-glycans were determined by using a hydrolysis and
GC-MS strategy. This method estimates the linkage type of the
carbohydrates to the peptide and the general monosaccharide
composition of a glycoprotein. Based on prior knowledge and also
the ratios between various monosaccharides, this method may suggest
the types of glycans on the glycoprotein. This information is
important to estimate the possible glycan structures present on the
protein.
[0260] Another method featured oligosaccharide analysis of the
N-glycan population. FAB-MS and MALDI-TOF MS were performed,
following digestion of aliquots of the samples with trypsin and
peptide N-glycosidase F (PNGaseF) and permethylation of the
glycans. This method is used to detach and isolate N-linked
carbohydrates from the enzymatically digested glycoprotein. The
masses of the glycan populations in the isolated glycan mix are
determined and their masses are compared with those of known
structures from databases and in light of the monosaccharide
composition analysis. The proposed structures are based also on the
glycosylation patterns of the source organism.
[0261] Another method included analyzing the O-glycan population
following reductive elimination of the tryptic and PNGase F treated
glycopeptides, desalting and permethylation. O-glycans are not
released by PNGase F, therefore, glycans remaining linked to
peptides are most likely O-linked glycans. These glycans are then
released by reductive elimination and their mass analyzed.
[0262] Monosaccharide composition analysis (summarized below)
revealed a characteristic distribution of hexoses, hexosamines and
pentoses characteristic of plant glycosylation. The ratios between
GlcNac and Mannose, suggest that characteristic N-linked structures
are the predominant glycan population.
[0263] Mass Spectrometric analysis of the N-glycans from hGCD
produced as described above indicates that the predominant N-glycan
population has the monosaccharide composition
Pent.deoxyHex.Hex3.HexNAc2.
Materials and Methods
[0264] Analysis was performed using a combination of Gas
Chromatography-Mass Spectrometry (GC-MS), Fast Atom
Bombardment-Mass Spectrometry (FAB-MS) and Delayed
Extraction-Matrix Assisted Laser Desorption Ionisation-Time of
Flight Mass-Spectrometry (DE-MALDI-TOF MS).
[0265] For oligosaccharide analysis, the N-glycan population was
analyzed by FAB-MS and MALDI-TOF MS following digestion of aliquots
of the samples with trypsin and peptide N-glycosidase F (PNGaseF)
and permethylation of the glycans. The O-glycan population was
analyzed following reductive elimination of the tryptic and PNGase
F treated glycopeptides, desalting and permethylation.
[0266] The monosaccharide linkages for both N- and O-glycans were
determined using a hydrolysis, derivatisation GC-MS strategy.
Experimental Description
[0267] Sample
[0268] The sample vials were received were given the unique sample
numbers as follows (Table 1):
TABLE-US-00001 TABLE 1 reference Product number Glucocerebrosidase.
Four tubes containing 62995 1 ml of sample each at a stated 62996
concentration of 0.8 mg/ml in 25 mM 62997 Citrate Buffer pH6.0,
0.01% Tween 80 62998
[0269] The samples were stored between -10 and -30.degree. C. until
required.
Protein Chemistry
[0270] Dialysis of Intact Samples
[0271] One vial (containing 1 ml of protein at a stated
concentration of 0.8 mg/ml) was injected into a Slide-A-Lyzer
dialysis cassette (10 kDa molecular weight cutoff) and dialysed at
4.degree. C. over a period of 24 hours against water, the water
being changed 3 times. Following dialysis the sample was removed
from the cassette and lyophilised.
Trypsin Digestion of the Intact Samples for Oligosaccharide
Screening
[0272] The dialysed, lyophilised sample was resuspended in 50 mM
ammonium bicarbonate buffer adjusted to pH 8.4 with 10% aq. ammonia
and digested with TPCK treated trypsin for 4 hours at 37.degree. C.
according to SOPs B001 and B003. The reaction was terminated by
placing in a heating block at 95.degree. C. for 2 minutes followed
by lyophilisation.
Carbohydrate Chemistry
Peptide N-Glycosidase A Digestion
[0273] The tryptically cleaved peptide/glycopeptide mixtures from
the glycoprotein sample was treated with the enzyme peptide
N-glycosidase A (PNGaseA) in ammonium acetate buffer, pH 5.5 at
37.degree. C. for 15 hours. The reaction was stopped by
freeze-drying. The resulting products were purified using a
C.sub.18 Sep-Pak cartridge.
Reductive Elimination
[0274] The Sep-Pak fraction containing potential O-linked
glycopeptides was dissolved in a solution of 10 mg/ml sodium
borohydride in 0.05M sodium hydroxide and incubated at 45.degree.
C. for 16 hours. The reaction was terminated by the addition of
glacial acetic acid.
Desalting of Reductively Eliminated Material
[0275] Desalting using Dowex beads was performed according to SOP
B022. The sample was loaded onto the column and eluted using 4 ml
of 5% aq. acetic acid. The collected fraction was lyophilised.
Permethylation of Released Carbohydrates
[0276] N-linked carbohydrates eluting in the 5% aq. acetic acid
Sep-Pak fraction and potential O-linked glycans released by
reductive elimination, were permethylated using the sodium
hydroxide (NaOH)/methyl iodide (MeI) procedure (SOP B018). A
portion of the permethylated N-linked glycan mixture was analyzed
by FAB-MS and MALDI-TOF MS and the remainder was subjected to
linkage analysis.
Linkage Analysis of the N-Linked Carbohydrate
[0277] Derivatisation
[0278] The permethylated glycan sample mixtures obtained following
tryptic and PNGase A digestion or reductive elimination were
hydrolysed (2M TFA, 2 hours at 120.degree. C.) and reduced (sodium
borodeuteride (NaBD.sub.4) in 2M NH.sub.4OH, 2 hours at room
temperature, SOP B025). The borate produced on the decomposition of
the borodeuteride was removed by 3 additions of a mixture of
methanol in glacial acetic acid (90:10) followed by lyophilisation.
The samples were then acetylated using acetic anhydride (1 hour at
100.degree. C.). The acetylated samples were purified by extraction
into chloroform. The partially methylated alditol acetates were
then examined by gas chromatography/mass spectrometry (GC/MS).
Standard mixtures of partially methylated alditol acetates and a
blank were also run under the same conditions.
[0279] Gas Liquid Chromatography/Mass Spectrometry (GC/MS)
[0280] An aliquot (1 .mu.l) of the derivatised carbohydrate samples
dissolved in hexane, were analyzed by GC/MS using a Perkin Elmer
Turbomass Gold mass spectrometer with an Autosystem XL gas
chromatograph and a Dell data system under the following
conditions:
[0281] Gas Chromatography
[0282] Column: DB5
[0283] Injection: On-column
[0284] Injector Temperature: 40.degree. C.
[0285] Programme: 1 minute at 40.degree. C. then 70.degree.
C./minute to 100.degree. C., held at 100.degree. C. for 1 minute,
then 8.degree. C./minute to 290.degree. C., finally held at
290.degree. C. for 5 minutes.
[0286] Carrier Gas: Helium
[0287] Mass Spectrometry
[0288] Ionisation Voltage: 70 eV
[0289] Acquisition Mode: Scanning
[0290] Mass Range: 35-450 Daltons
[0291] MS Resolution: Unit
Sugar Analysis of Intact Glucocerebrosidase
[0292] Derivatisation
[0293] An aliquot equivalent to 500 .mu.g of glucocerebrosidase was
lyophilised with 10 .mu.g of Arabitol as internal standard. This
was then methanolysed overnight at 80.degree. C. and dried under
nitrogen. Released monosaccharides were re-N-acetylated using a
solution of methanol, pyridine and acetic anhydride, dried under
nitrogen again and converted to their trimethylsilyl (TMS)
derivatives according to SOP B023. The TMS derivatives were reduced
in volume under nitrogen, dissolved in 2 ml of hexane and sonicated
for 3 minutes. The samples were then allowed to equilibrate at
4.degree. C. overnight. A blank containing 10 .mu.g of Arabitol and
a standard monosaccharide mixture containing 10 .mu.g each of
Fucose, Xylose, Mannose, Galactose, Glucose, N-acetylgalactosamine,
N-acetylglucosamine, N-acetylneuraminic acid and Arabitol were
prepared in parallel. The TMS derivatives were then examined by gas
chromatography/mass spectrometry (GC/MS).
Gas Liquid Chromatography/Mass Spectrometry
[0294] (GC/MS)
[0295] An aliquot (1 .mu.l) of the derivatised carbohydrate sample
dissolved in hexane, was analyzed by GC/MS using a Perkin Elmer
Turbomass Gold mass spectrometer with an Autosystem XL gas
chromatograph and a Dell data system under the following
conditions:
[0296] Gas Chromatography
[0297] Column: DB5
[0298] Injection: On-column
[0299] Injector Temperature: 40.degree. C.
[0300] Programme: 1 minute at 90.degree. C. then 25.degree.
C./minute to 140.degree. C., 5.degree. C./minute to 220.degree. C.,
finally 10.degree. C./minute to 300.degree. C. and held at
300.degree. C. for 5 minutes.
[0301] Carrier Gas: Helium
[0302] Mass Spectrometry
[0303] Ionisation Voltage: 70 eV
[0304] Acquisition Mode Scanning
[0305] Mass Range: 50-620 Daltons
[0306] MS Resolution: Unit
Delayed Extraction Matrix Assisted Laser Desorption Ionisation Mass
Spectrometry (DE-MALDI-MS) and Fast Atom Bombardment-Mass
Spectrometry (FAB-MS)
[0307] MALDI-TOF mass spectrometry was performed using a Voyager
STR Biospectrometry Research Station Laser-Desorption Mass
Spectrometer coupled with Delayed Extraction (DE).
[0308] Dried permethylated glycans were redissolved in
methanol:water (80:20) and analyzed using a matrix of
2,5-dihydroxybenzoic acid. Bradykinin, Angiotensin and ACTH were
used as external calibrants.
[0309] Positive Ion Fast Atom Bombardment mass spectrometric
analyses were carried out on M-Scan's VG AutoSpecE mass
spectrometer operating at Vacc=8 kV for 4500 mass range at full
sensitivity with a resolution of approximately 2500. A Caesium Ion
Gun was used to generate spectra operating at 30 kV. Spectra were
recorded on a VAX data system 3100 M76 using Opus software.
[0310] Dried permethylated glycans were dissolved in methanol and
loaded onto a target previously smeared with 2-4 .mu.l of
thioglycerol as matrix prior to insertion into the source.
[0311] In a second set of glycosylation analysis, similar methods
were used to determine the glycosylation patterns, and to identify
the major glycosylated products produced by the carrot cell
suspension culture of the present invention:
[0312] Glycosylation patterns were analyzed by the Glycobiology
Center of the National Institute for Biotechnology (Ben Gurion
University, Beer Sheba, Israel) to determine glycan structure and
relative amounts using sequential digestion with various
exoglycosidases. The plant GCD samples of the invention were run on
SDS-PAGE and a 61 KDa band was cut out and incubated with either
PNGase A, or with trypsin followed by PNGase A to release the
N-linked glycans. The glycans were fluorescently labeled with
anthranilamide (2AB) and run on normal phase HPLC.
[0313] Sequencing of the labeled glycan pool was achieved by
sequential digestion with various exoglycosidases followed by HPLC
analysis. Retention times of individual glycans were compared to
those of a standard partial hydrolysate of dextran giving a ladder
of glucose units (GU). Unlabeled glycans were further purified and
analyzed by MALDI mass spectrometry. Exoglycosidases used: Bovine
kidney_-fucosidase (digests.sub.--1-6 and .sub.--1-3 core fucose,
Prozyme), Jack bean mannosidase (removes.sub.--1-2, 6>3 mannose,
Prozyme), Xanthomonas beta1,2-xylosidase (removes.sub.--1-2 xylose
only after removal of _-linked mannose, Calbiochem).
[0314] Bovine testes--galactosidase (hydrolyses non-reducing
terminal galactose.sub.--1-3 and .sub.--1-4 linkages, Prozyme),
Streptococcus pneumoniae hexosaminidase (digest.sub.--1-2,3,4,6
GalNAc and GlcNAc, Prozyme). Glycosylation was further analyzed by
M-Scan (Berkshire, England) using gas chromatography mass
spectrometry (GC-MS), fast atom bombardment-mass spectrometry
(FAB-MS), and delayed extraction-matrix assisted laser desorption
ionization--time of flight mass-spectrometry (DE-MALDI-TOF MS). For
oligosaccharide determination, the N-glycan population was analyzed
by FAB-MS and MALDI-TOF MS, following digestion of samples with
trypsin and PNGase A, and permethylation of the glycans. O-glycans
were analyzed following reductive elimination of the tryptic and
PNGase A-treated glycopeptides, desalting and permethylation.
[0315] The similarity of the N-glycans in different batches of
prGCD was analyzed by high performance anion exchange
chromatography with pulsed amperometric detection (HPAEC-PAD, a
Dionex method) following digestion with trypsin and PNGase A, to
obtain chromatographic profiles for oligosaccharides released from
glycoproteins for the purpose of demonstrating consistency from
batch to batch of prGCD. This procedure permits chromatographic
comparison of oligosaccharide patterns in a qualitative and
quantitative manner.
[0316] Results and Discussion
TMS Sugar Analysis of Glucocerebrosidase
N-Linked Oligosaccharide Screening
[0317] The intact glycoprotein was subjected to dialysis followed
by trypsin digestion and the lyophilised products were digested
using PNGase A and then purified using a C.sub.18 Sep-Pak. The 5%
aq. acetic acid (N-linked oligosaccharide containing) fraction was
permethylated and FAB mass spectra were obtained using a portion of
the derivatised oligosaccharide in a low mass range for fragment
ions and DE-MALDI-TOF mass spectra were obtained using a portion of
the derivatised oligosaccharides in a high mass range for molecular
ions.
Analysis of N-Glycans from Glucocerebrosidase
[0318] Table 1 lists the predominant fragment ions present in the
FAB spectra and molecular ions present in the MALDI spectra. The
molecular ion region (shown in Appendix III) contains a predominant
signal at m/z 1505.8 (consistent with an [M+Na].sup.+
quasimolecular ion for a structure having the composition
Pent.deoxyHex.Hex.sub.3.HexNAc.sub.2). A range of less intense
quasimolecular ions were also detected consistent with complex and
high mannose structures. The high mannose structures detected range
in size from Hex.sub.5.HexNAc.sub.2 at m/z 1579.8 to
Hex.sub.8.HexNAc.sub.2 at m/z 2193.0. The complex signals are
produced from less extensively processed N-glycans such as m/z
1331.7 (consistent with an [M+Na].sup.+ quasimolecular ion for a
structure having the composition Pent.Hex.sub.3.HexNAc.sub.2) or
from larger N-glycans for example m/z 1751.0 (consistent with an
[M+Na].sup.+ quasimolecular ion for a structure having the
composition Pent.deoxyHex.Hex.sub.3.HexNAc.sub.3), m/z 2375.4
(consistent with an [M+Na].sup.+ quasimolecular ion for a structure
having the composition Pent.deoxyHex.sub.2.Hex.sub.4.HexNAc.sub.4)
and m/z 2753.6 (consistent with an [M+Na].sup.+ quasimolecular ion
for a structure having the composition
Pent.deoxyHex.sub.3.Hex.sub.5.HexNAc.sub.4).
[0319] The FAB mass spectrum provides information regarding
antennae structures by virtual of fragment ions in the low mass
region of the spectrum (data not shown). Signals were detected
identifying hexose (at m/z 219) and HexNAc (at m/z 260) as
non-reducing terminal monosaccharides in the N-glycans.
TABLE-US-00002 TABLE 2 Masses observed in the permethylated spectra
of Glucocerebrosidase (reference number 62996) following Tryptic
and Peptide N-glycosidase A digestion Signals observed (m/z)
Possible Assignment Low Mass 219 Hex.sup.+ 228 HexNAc.sup.+ (-
methanol) 260 HexNAc.sup.+ High Mass 1032.4
Pent.Hex.sub.3.HexNAc.sup.+ 1171.5 Hex.sub.3.HexNAc.sub.2OMe +
Na.sup.+ 1299.6 Elimination of fucose from m/z 1505.8 1331.6
Pent.Hex.sub.3.HexNAc.sub.2OMe + Na.sup.+ 1345.6
deoxyHex.Hex.sub.3.HexNAc.sub.2OMe + Na.sup.+ 1505.7
Pent.deoxyHex.Hex.sub.3.HexNAc.sub.2OMe + Na.sup.+ 1579.8
Hex.sub.5.HexNAc.sub.2OMe + Na.sup.+ 1709.9
Pent.deoxyHex.Hex.sub.4.HexNAc.sub.2OMe + Na.sup.+ 1750.9
Pent.deoxyHex.Hex.sub.3.HexNAc.sub.3OMe + Na.sup.+ 1783.9
Hex.sub.6.HexNAc.sub.2OMe + Na.sup.+ 1989.0
Hex.sub.7.HexNAc.sub.2OMe + Na.sup.+ 1997.0
Pent.deoxyHex.Hex.sub.3.HexNAc.sub.4OMe + Na.sup.+ 2027.0 Not
assigned 2099.0 Not assigned 2130.0
Pent.deoxyHex.sub.2.Hex.sub.4.HexNAc.sub.3OMe + Na.sup.+ 2193.1
Hex.sub.8.HexNAc.sub.2OMe + Na.sup.+ 2375.2
Pent.deoxyHex.sub.2.Hex.sub.4.HexNAc.sub.4OMe + Na.sup.+ 2753.4
Pent.deoxyHex.sub.3.Hex.sub.5.HexNAc.sub.4OMe + Na.sup.+
[0320] All masses in column one are monoisotopic unless otherwise
stated. The mass numbers may not relate directly to the raw data as
the software often assigns mass numbers to .sup.13C isotope peaks
particularly for masses above 1700 Da.
Linkage Analysis of N-Glycans from Glucocerebrosidase
[0321] Linkage analysis was performed on the N-linked carbohydrates
released following PNGase A digestion, Sep-Pak purification and
permethylation.
[0322] A complex chromatogram was obtained with some impurity peaks
originating from the derivatising reagents. Comparison of the
retention time and the spectra with standard mixtures allowed
provisional assignments of the sugar containing peaks listed in
Table 3.
TABLE-US-00003 TABLE 3 Retention times of the variously linked
monosaccharides detected as their partially methylated alditol
acetates in the GC-MS analysis of Glucocerebrosidase (reference
number 62996) following Tryptic and Peptide N-glycosidase A
digestion Retention time Compounds (mins) Glucocerebrosidase
Observed (62996) Terminal 10.41 Xylose Terminal 10.84 Fucose
Terminal 12.29 (major) Mannose Terminal 12.55 Galactose 2-linked
13.40 Mannose 4-linked 13.58 Glucose 2,6-linked 14.91 Mannose
3,6-linked 15.08 Mannose 2,3,6-linked 15.87 Mannose 4-linked 16.73
GlcNAc 3,4-linked 17.59 GlcNAc
[0323] 4.3 O-Linked Oligosaccharide Screening
[0324] Reductive elimination was carried out on the 60% 2-propanol
fraction (potential O-linked glycopeptide fraction) from the
Sep-Pak purification of Glucocerebrosidase following trypsin and
PNGase A digestions. The sample was desalted following termination
of the reaction and, after borate removal, was permethylated. FAB
mass spectra were obtained using a portion of the derivatised
oligosaccharide in a low mass range for fragment ions and
DE-MALDI-TOF mass spectra were obtained using a portion of the
derivatised oligosaccharides in a high mass range for molecular
ions. No signals consistent with the presence of O-linked glycans
were observed (data not shown).
Linkage Analysis of O-Glycans from Glucocerebrosidase
[0325] Linkage analysis was carried out on the products of
reductive elimination after permethylation. No signals consistent
with the presence of typical O-linked glycans were observed (data
not shown).
[0326] FIG. 6 shows some exemplary glycan structures as a
comparison between GCD obtained from CHO (Chinese hamster ovary)
cells, which are mammalian cells (Cerezyme.TM.) and the GCD of the
present invention, from carrot cells. As shown, remodeling of these
structures is required to obtain exposed mannose residues for
Cerezyme.TM.. By contrast, such exposed mannose residues are
directly obtained for the GCD obtained from plant cells according
to the present invention, without requiring further manipulation,
for example with glycosylases.
[0327] FIG. 7 represents the main glycan structure found in rGCD.
FIG. 7 shows proposed structures of: a) the predominant
oligosaccharide population found on hGC expressed in carrot cell
suspension (1505.7 m/z); b) typical N-linked core; c) Fucosylated
plant N-linked core. N-linked glycans are coupled to the protein
via-Aspargine and through the reducing end of the GlcNac (GN)
residue on the right hand of the diagrams. N plant glycosylation
patterns, Fucose residues may be part of the core structure, bound
to the first GlcNac using an alpha(1-3) glycosidic bond, while
mammalian structures typically use the alpha(1-6) glycosidic
bond.
[0328] FIGS. 8A-8D show all possible structures for the N-glycans
detected on the rGCD protein according to the present
invention.
[0329] The dominant glycan structure that was identified is the
core glycan structure found in most plant glycoproteins from pea,
rice, maize and other edible plants. This structure contains a core
xylose residue as well as a core alpha-(1,3)-fucose. Work done by
Bardor et al (33) shows that 50% of nonallergic blood donors have
specific antibodies for core xylose in their sera, and 25% have
specific antibodies to core alpha-(1,3)-fucose. However it is still
to be studied whether such antibodies might introduce limitations
to the use of plant-derived biopharmaceutical glycoproteins.
[0330] The minor glycan populations of the hGCD produced as
described above were mainly high mannose structures Hex4HexNAc2 to
Hex8HexNAc2. Among the complex structures exhibited structures such
as Pent.deoxyHex2.Hex4.HexNAc3 and Pent.deoxyHex3.Hex5.HexNAc3.
Pent.Hex3.HexNAc2 was detected in smaller proportions.
[0331] The major terminal monosaccharides are hexose (Mannose or
Galactose) and N-acetylhexosamine, which is consistent with the
presence of high mannose structures and partially processed complex
structures.
[0332] With regard to O-linked oligosaccharide screening, no
signals that are consistent with typical O-linked glycans were
observed. GCD is known in the art to not have O-linked
oligosaccharides, such that these results are consistent with the
known glycosylation of GCD from other cell systems, including
native GCD and recombinant GCD produced in mammalian culture
systems. However, in the monosaccharide composition, signals
consistent with Arabinose were detected.
[0333] An important point with regard to the present invention is
that the hGCD protein N-glycan composition analysis showed that the
majority of the N-glycans terminate with mannose residues. This
agrees with the requirement for mannose terminating N-glycans
assisting the uptake of therapeutic hGCD by the macrophage mannose
receptor. However, neither native GCD nor recombinant GCD produced
in mammalian cells is high mannose. Therefore, the present
invention overcomes a significant drawback of commercially produced
hGCD proteins, which is that these proteins are modified to
terminate with mannose sugars, unlike the protein produced as
described above.
[0334] Further glycosylation analysis was performed on a purified
human recombinant glucocerebrosidase prepared in plant cells.
Glycosylation was analyzed (Glycobiology Center of the National
Institute for Biotechnology (Ben Gurion University, Beer Sheba,
Israel) to determine glycan structure and the glycan quantitative
ratio using sequential digestion with various exoglycosidases (see
Methods, above). In this analysis, it was found that the N-linked
glycans have a main core of two GlcNAc residues and a 1-4 linked
mannose, attached to two additional mannose residues in .sub.--1-3
and .sub.--1-6 linkages. The additional residues found are shown in
FIG. 10a, which presents all structures and their relative amounts
based upon HPLC, enzyme array digests and MALDI. FIG. 10b shows the
glycan structure of Cerezyme.RTM. before and after in vitro
enzymatic processing. Notably, analysis of the glycan structures of
the GCD of the invention revealed that >90% of the glycans were
mannose-rich, bearing exposed, terminal mannose residues (FIG.
10a), whereas in the case of Cerezyme.RTM., mannose residues are
exposed only after a complex in-vitro procedure (FIG. 10b). The
dominant glycan in the GCD of the invention is the core structure
found in most glycoproteins purified from pea, rice, maize and
other edible plants. This structure contains a core_-(1,2)-xylose
residue as well as a core_-(1,3)-fucose (FIG. 10a). The DE-MALDI-MS
data contained no signals consistent with typical O-linked glycans.
Further analysis of the glycan profiles for the GCD of the
invention obtained from different production batches was performed
in order to assess the batch-to-batch reproducibility of the GCD
produced in the carrot cell system. As presented in FIG. 11, the
population of glycans on plant GCD of the invention is highly
reproducible between batches.
Example 6
Treatment with the Present Invention
[0335] The recombinant protein produced according to the present
invention preferably comprises a suitably glycosylated protein
produced by a plant cell culture, which is preferably a lysosomal
enzyme for example, and/or a high mannose glycosylated protein.
[0336] According to preferred embodiments herein, the protein
produced according to the present invention is suitable for
treatment of a lysosomal-associated disease, such as a lysosomal
storage disease for example.
[0337] The method of treatment optionally and preferably comprises:
(a) providing a recombinant biologically active form of lysosomal
enzyme purified from transformed plant root cells, and capable of
efficiently targeting cells abnormally deficient in the lysosomal
enzyme. This recombinant biologically active enzyme has exposed
terminal mannose residues on appended oligosaccharides; and (b)
administering a therapeutically effective amount of the recombinant
biologically active lysosomal enzyme, or of composition comprising
the same to the subject. In a preferred embodiment, the recombinant
high mannose lysosomal enzyme used by the method of the invention
may be produced by the host cell of the invention. Preferably, this
host cell is a carrot cell.
[0338] By "mammalian subject" or "mammalian patient" is meant any
mammal for which gene therapy is desired, including human, bovine,
equine, canine, and feline subjects, most preferably, a human
subject.
[0339] It should be noted that the term "treatment" also includes
amelioration or alleviation of a pathological condition and/or one
or more symptoms thereof, curing such a condition, or preventing
the genesis of such a condition.
[0340] In another preferred embodiment, the lysosomal enzyme used
by the method of the invention may be a high mannose enzyme
comprising at least one oligosaccharide chain having an exposed
mannose residue. This recombinant enzyme can bind to a mannose
receptor on a target cell in a target site within a subject. More
preferably, this recombinant lysosomal enzyme has increased
affinity for these target cell, in comparison with the
corresponding affinity of a naturally occurring lysosomal enzyme to
the target cell. Therefore, each dose is dependent on the effective
targeting of cells abnormally deficient in GCD and each dose of
such form of GCD is substantially less than the dose of naturally
occurring GCD that would otherwise be administered in a similar
manner to achieve the therapeutic effect.
[0341] According to preferred embodiments of the present invention,
the protein is suitable for the treatment of lysosomal storage
diseases, such that the present invention also comprises a method
for treating such diseases. Lysosomal storage diseases are a group
of over 40 disorders which are the result of defects in genes
encoding enzymes that break down glycolipid or polysaccharide waste
products within the lysosomes of cells. The enzymatic products,
e.g., sugars and lipids, are then recycled into new products. Each
of these disorders results from an inherited autosomal or X-linked
recessive trait which affects the levels of enzymes in the
lysosome. Generally, there is no biological or functional activity
of the affected enzymes in the cells and tissues of affected
individuals. In such diseases the deficiency in enzyme function
creates a progressive systemic deposition of lipid or carbohydrate
substrate in lysosomes in cells in the body, eventually causing
loss of organ function and death. The genetic etiology, clinical
manifestations, molecular biology and possibility of the lysosomal
storage diseases are detailed in Scriver et al. [Scriver et al.
eds., The Metabolic and Molecular Basis of Inherited Disease,
7.sup.th Ed., Vol. II, McGraw Hill, (1995)].
[0342] Examples of lysosomal storage diseases (and their associated
deficient enzymes) include but are not limited to Fabry disease
(.alpha.-galactosidase), Farber disease (ceramidase), Gaucher
disease (glucocerebrosidase), G.sub.ml gangliosidosis
(.beta.-galactosidase), Tay-Sachs disease (.beta.-hexosaminidase),
Niemann-Pick disease (sphingomyelinase), Schindler disease
(.alpha..-N-acetylgalactosaminidase), Hunter syndrome
(iduronate-2-sulfatase), Sly syndrome (.beta.-glucuronidase),
Hurler and Hurler/Scheie syndromes (iduronidase), and I-Cell/San
Filipo syndrome (mannose 6-phosphate transporter).
[0343] Gaucher disease is the most common lysosomal storage disease
in humans, with the highest frequency encountered in the Ashkenazi
Jewish population. About 5,000 to 10,000 people in the United
States are afflicted with this disease [Grabowski, Adv. Hum. Genet.
21:377-441 (1993)]. Gaucher disease results from a deficiency in
glucocerebrosidase (hGCD; glucosylceramidase). This deficiency
leads to an accumulation of the enzyme's substrate,
glucocerebroside, in reticuloendothelial cells of the bone marrow,
spleen and liver, resulting in significant skeletal complications
such as bone marrow expansion and bone deterioration, and also
hypersplenism, hepatomegaly, thrombocytopenia, anemia and lung
complications [Grabowski, (1993) ibid.; Lee, Prog. Clin. Biol. Res.
95:177-217 (1982)].
[0344] More specifically, the lysosomal enzyme used by the method
of the invention may be selected from the group consisting of
glucocerebrosidase (GCD), acid sphingomyelinase, hexosaminidase,
.alpha.-N-acetylgalactosaminidise, acid lipase,
.alpha.-galactosidase, glucocerebrosidase, .alpha.-L-iduronidase,
iduronate sulfatase, .alpha.-mannosidase or sialidase. Preferably,
where the treated disease is Gaucher's disease, the lysosomal
enzyme used by the method of the invention is glucocerebrosidase
(GCD).
[0345] The protein of the present invention can be used to produce
a pharmaceutical composition. Thus, according to another aspect of
the present invention there is provided a pharmaceutical
composition which includes, as an active ingredient thereof, a
protein and a pharmaceutical acceptable carrier. As used herein a
"pharmaceutical composition" refers to a preparation of one or more
of the active ingredients described herein, such as a recombinant
protein, with other chemical components such as traditional drugs,
physiologically suitable carriers and excipients. The purpose of a
pharmaceutical composition is to facilitate administration of a
protein or cell to an organism. Pharmaceutical compositions of the
present invention may be manufactured by processes well known in
the art, e.g., by means of conventional mixing, dissolving,
granulating, dragee-making, levigating, emulsifying, encapsulating,
entrapping or lyophilizing processes.
[0346] In a preferred embodiment, the term "pharmaceutically
acceptable" means approved by a regulatory agency of the Federal or
a state government or listed in the U.S. Pharmacopeia or other
generally recognized pharmacopeia for use in animals, and more
particularly in humans. Hereinafter, the phrases "physiologically
suitable carrier" and "pharmaceutically acceptable carrier" are
interchangeably used and refer to an approved carrier or a diluent
that does not cause significant irritation to an organism and does
not abrogate the biological activity and properties of the
administered conjugate.
[0347] The term "carrier" refers to a diluent, adjuvant, excipient,
or vehicle with which the therapeutic is administered. Such
pharmaceutical carriers can be sterile liquids, such as water and
oils, including those of petroleum, animal, vegetable or synthetic
origin, such as peanut oil, soybean oil, mineral oil, sesame oil
and the like. Water is a preferred carrier when the pharmaceutical
composition is administered intravenously. Saline solutions and
aqueous dextrose and glycerol solutions can also be employed as
liquid carriers, particularly for injectable solutions. Suitable
pharmaceutical excipients include starch, glucose, lactose,
sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium
stearate, glycerol monostearate, talc, sodium chloride, dried skim
milk, glycerol, propylene, glycol, water, ethanol and the like. The
composition, if desired, can also contain minor amounts of wetting
or emulsifying agents, or pH buffering agents. These compositions
can take the form of solutions, suspensions, emulsion, tablets,
pills, capsules, powders, sustained-release formulations and the
like. The composition can be formulated as a suppository, with
traditional binders and carriers such as triglycerides. Oral
formulation can include standard carriers such as pharmaceutical
grades of mannitol, lactose, starch, magnesium stearate, sodium
saccharine, cellulose, magnesium carbonate, etc. Examples of
suitable pharmaceutical carriers are described in "Remington's
Pharmaceutical Sciences" by E. W. Martin. Such compositions will
contain a therapeutically effective amount of the protein,
preferably in purified form, together with a suitable amount of
carrier so as to provide the form for proper administration to the
patient. The formulation should be suitable for the mode of
administration.
[0348] Herein the term "excipient" refers to an inert substance
added to a pharmaceutical composition to further facilitate
processes and administration of the active ingredients. Examples,
without limitation, of excipients include calcium carbonate,
calcium phosphate, various sugars and types of starch, cellulose
derivatives, gelatin, vegetable oils and polyethylene glycols.
[0349] Further techniques for formulation and administration of
active ingredients may be found in "Remington's Pharmaceutical
Sciences," Mack Publishing Co., Easton, Pa., latest edition, which
is incorporated herein by reference as if fully set forth
herein.
[0350] The pharmaceutical compositions herein described may also
comprise suitable solid or gel phase carriers or excipients.
Examples of such carriers or excipients include, but are not
limited to, calcium carbonate, calcium phosphate, various sugars,
starches, cellulose derivatives, gelatin and polymers such as
polyethylene glycols.
[0351] Suitable routes of administration may, for example, include
oral, rectal, transmucosal, transdermal, intestinal or parenteral
delivery, including intramuscular, subcutaneous and intramedullary
injections as well as intrathecal, direct intraventricular,
intravenous, intraperitoneal, intranasal, or intraocular
injections.
[0352] Pharmaceutical compositions for use in accordance with the
present invention thus may be formulated in conventional manner
using one or more pharmaceutically acceptable carriers comprising
excipients and auxiliaries, which facilitate processing of the
active ingredients into preparations which, can be used
pharmaceutically. Proper formulation is dependent upon the route of
administration chosen.
[0353] For injection, the active ingredients of the invention may
be formulated in aqueous solutions, preferably in physiologically
compatible buffers such as Hank's solution, Ringer's solution, or
physiological saline buffer. For transmucosal administration,
penetrants are used in the formulation. Such penetrants are
generally known in the art.
[0354] For oral administration, the active ingredients can be
optionally formulated through administration of the whole cells
producing a protein according to the present invention, such as GCD
for example. The active ingredients can also be formulated by
combining the active ingredients and/or the cells with
pharmaceutically acceptable carriers well known in the art. Such
carriers enable the active ingredients of the invention to be
formulated as tablets, pills, dragees, capsules, liquids, gels,
syrups, slurries, suspensions, and the like, for oral ingestion by
a patient. Pharmacological preparations for oral use can be made
using a solid excipient, optionally grinding the resulting mixture,
and processing the mixture of granules, after adding suitable
auxiliaries if desired, to obtain tablets or dragee cores. Suitable
excipients are, in particular, fillers such as sugars, including
lactose, sucrose, mannitol, or sorbitol; cellulose preparations
such as, for example, maize starch, wheat starch, rice starch,
potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or
physiologically acceptable polymers such as polyvinylpyrrolidone
(PVP). If desired, disintegrating agents may be added, such as
cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt
thereof such as sodium alginate.
[0355] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, titanium dioxide, lacquer
solutions and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active ingredient doses.
[0356] Pharmaceutical compositions, which can be used orally,
include push-fit capsules made of gelatin as well as soft, sealed
capsules made of gelatin and a plasticizer, such as glycerol or
sorbitol. The push-fit capsules may contain the active ingredients
in admixture with filler such as lactose, binders such as starches,
lubricants such as talc or magnesium stearate and, optionally,
stabilizers. In soft capsules, the active ingredients may be
dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. All formulations for oral administration
should be in dosages suitable for the chosen route of
administration.
[0357] For buccal administration, the compositions may take the
form of tablets or lozenges formulated in conventional manner.
[0358] For administration by inhalation, the active ingredients for
use according to the present invention are conveniently delivered
in the form of an aerosol spray presentation from a pressurized
pack or a nebulizer with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichloro-tetrafluoroethane or carbon dioxide. In the case of a
pressurized aerosol, the dosage unit may be determined by providing
a valve to deliver a metered amount. Capsules and cartridges of,
e.g., gelatin for use in an inhaler or insufflator may be
formulated containing a powder mix of the active ingredient and a
suitable powder base such as lactose or starch.
[0359] The active ingredients described herein may be formulated
for parenteral administration, e.g., by bolus injection or
continuous infusion. Formulations for injection may be presented in
unit dosage form, e.g., in ampoules or in multidose containers with
optionally, an added preservative. The compositions may be
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents.
[0360] Pharmaceutical compositions for parenteral administration
include aqueous solutions of the active preparation in
water-soluble form. Additionally, suspensions of the active
ingredients may be prepared as appropriate oily injection
suspensions. Suitable lipophilic solvents or vehicles include fatty
oils such as sesame oil, or synthetic fatty acids esters such as
ethyl oleate, triglycerides or liposomes. Aqueous injection
suspensions may contain substances, which increase the viscosity of
the suspension, such as sodium carboxymethyl cellulose, sorbitol or
dextran. Optionally, the suspension may also contain suitable
stabilizers or agents which increase the solubility of the active
ingredients to allow for the preparation of highly concentrated
solutions.
[0361] In a preferred embodiment, the composition is formulated in
accordance with routine procedures as a pharmaceutical composition
adapted for intravenous administration to human beings. Typically,
pharmaceutical compositions for intravenous administration are
solutions in sterile isotonic aqueous buffer. Generally, the
ingredients are supplied either separately or mixed together in
unit dosage form, for example, as a dry lyophilized powder or water
free concentrate in a hermetically sealed container such as an
ampoule or sachette indicating the quantity of active agent. Where
the composition is to be administered by infusion, it can be
dispensed with an infusion bottle containing sterile pharmaceutical
grade water or saline. Where the composition is administered by
injection, an ampoule of sterile water for injection or saline can
be provided so that the ingredients may be mixed prior to
administration.
[0362] The pharmaceutical compositions of the invention can be
formulated as neutral or salt forms. Pharmaceutically acceptable
salts include those formed with anions such as those derived from
hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and
those formed with cations such as those derived from sodium,
potassium, ammonium, calcium, ferric hydroxides, isopropylamine,
triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
[0363] The active ingredients of the present invention may also be
formulated in rectal compositions such as suppositories or
retention enemas, using, e.g., conventional suppository bases such
as cocoa butter or other glycerides.
[0364] The pharmaceutical compositions herein described may also
comprise suitable solid of gel phase carriers or excipients.
Examples of such carriers or excipients include, but are not
limited to, calcium carbonate, calcium phosphate, various sugars,
starches, cellulose derivatives, gelatin and polymers such as
polyethylene glycols.
[0365] The topical route is optionally performed, and is assisted
by a topical carrier. The topical carrier is one which is generally
suited for topical active ingredient administration and includes
any such materials known in the art. The topical carrier is
selected so as to provide the composition in the desired form,
e.g., as a liquid or non-liquid carrier, lotion, cream, paste, gel,
powder, ointment, solvent, liquid diluent, drops and the like, and
may be comprised of a material of either naturally occurring or
synthetic origin. It is essential, clearly, that the selected
carrier does not adversely affect the active agent or other
components of the topical formulation, and which is stable with
respect to all components of the topical formulation. Examples of
suitable topical carriers for use herein include water, alcohols
and other nontoxic organic solvents, glycerin, mineral oil,
silicone, petroleum jelly, lanolin, fatty acids, vegetable oils,
parabens, waxes, and the like. Preferred formulations herein are
colorless, odorless ointments, liquids, lotions, creams and
gels.
[0366] Ointments are semisolid preparations, which are typically
based on petrolatum or other petroleum derivatives. The specific
ointment base to be used, as will be appreciated by those skilled
in the art, is one that will provide for optimum active ingredients
delivery, and, preferably, will provide for other desired
characteristics as well, e.g., emolliency or the like. As with
other carriers or vehicles, an ointment base should be inert,
stable, nonirritating and nonsensitizing. As explained in
Remington: The Science and Practice of Pharmacy, 19th Ed. (Easton,
Pa.: Mack Publishing Co., 1995), at pages 1399-1404, ointment bases
may be grouped in four classes: oleaginous bases; emulsifiable
bases; emulsion bases; and water-soluble bases. Oleaginous ointment
bases include, for example, vegetable oils, fats obtained from
animals, and semisolid hydrocarbons obtained from petroleum.
Emulsifiable ointment bases, also known as absorbent ointment
bases, contain little or no water and include, for example,
hydroxystearin sulfate, anhydrous lanolin and hydrophilic
petrolatum. Emulsion ointment bases are either water-in-oil (W/O)
emulsions or oil-in-water (O/W) emulsions, and include, for
example, cetyl alcohol, glyceryl monostearate, lanolin and stearic
acid. Preferred water-soluble ointment bases are prepared from
polyethylene glycols of varying molecular weight; again, reference
may be made to Remington: The Science and Practice of Pharmacy for
further information.
[0367] Lotions are preparations to be applied to the skin surface
without friction, and are typically liquid or semiliquid
preparations, in which solid particles, including the active agent,
are present in a water or alcohol base. Lotions are usually
suspensions of solids, and may comprise a liquid oily emulsion of
the oil-in-water type. Lotions are preferred formulations herein
for treating large body areas, because of the ease of applying a
more fluid composition. It is generally necessary that the
insoluble matter in a lotion be finely divided. Lotions will
typically contain suspending agents to produce better dispersions
as well as active ingredients useful for localizing and holding the
active agent in contact with the skin, e.g., methylcellulose,
sodium carboxymethylcellulose, or the like.
[0368] Creams containing the selected active ingredients are, as
known in the art, viscous liquid or semisolid emulsions, either
oil-in-water or water-in-oil. Cream bases are water-washable, and
contain an oil phase, an emulsifier and an aqueous phase. The oil
phase, also sometimes called the "internal" phase, is generally
comprised of petrolatum and a fatty alcohol such as cetyl or
stearyl alcohol; the aqueous phase usually, although not
necessarily, exceeds the oil phase in volume, and generally
contains a humectant. The emulsifier in a cream formulation, as
explained in Remington, supra, is generally a nonionic, anionic,
cationic or amphoteric surfactant.
[0369] Gel formulations are preferred for application to the scalp.
As will be appreciated by those working in the field of topical
active ingredients formulation, gels are semisolid, suspension-type
systems. Single-phase gels contain organic macromolecules
distributed substantially uniformly throughout the carrier liquid,
which is typically aqueous, but also, preferably, contain an
alcohol and, optionally, an oil.
[0370] Various additives, known to those skilled in the art, may be
included in the topical formulations of the invention. For example,
solvents may be used to solubilize certain active ingredients
substances. Other optional additives include skin permeation
enhancers, opacifiers, anti-oxidants, gelling agents, thickening
agents, stabilizers, and the like.
[0371] The topical compositions of the present invention may also
be delivered to the skin using conventional dermal-type patches or
articles, wherein the active ingredients composition is contained
within a laminated structure, that serves as a drug delivery device
to be affixed to the skin. In such a structure, the active
ingredients composition is contained in a layer, or "reservoir",
underlying an upper backing layer. The laminated structure may
contain a single reservoir, or it may contain multiple reservoirs.
In one embodiment, the reservoir comprises a polymeric matrix of a
pharmaceutically acceptable contact adhesive material that serves
to affix the system to the skin during active ingredients delivery.
Examples of suitable skin contact adhesive materials include, but
are not limited to, polyethylenes, polysiloxanes, polyisobutylenes,
polyacrylates, polyurethanes, and the like. The particular
polymeric adhesive selected will depend on the particular active
ingredients, vehicle, etc., i.e., the adhesive must be compatible
with all components of the active ingredients-containing
composition. Alternatively, the active ingredients-containing
reservoir and skin contact adhesive are present as separate and
distinct layers, with the adhesive underlying the reservoir which,
in this case, may be either a polymeric matrix as described above,
or it may be a liquid or hydrogel reservoir, or may take some other
form.
[0372] The backing layer in these laminates, which serves as the
upper surface of the device, functions as the primary structural
element of the laminated structure and provides the device with
much of its flexibility. The material selected for the backing
material should be selected so that it is substantially impermeable
to the active ingredients and to any other components of the active
ingredients-containing composition, thus preventing loss of any
components through the upper surface of the device. The backing
layer may be either occlusive or non-occlusive, depending on
whether it is desired that the skin become hydrated during active
ingredients delivery. The backing is preferably made of a sheet or
film of a preferably flexible elastomeric material. Examples of
polymers that are suitable for the backing layer include
polyethylene, polypropylene, and polyesters.
[0373] During storage and prior to use, the laminated structure
includes a release liner. Immediately prior to use, this layer is
removed from the device to expose the basal surface thereof, either
the active ingredients reservoir or a separate contact adhesive
layer, so that the system may be affixed to the skin. The release
liner should be made from an active ingredients/vehicle impermeable
material.
[0374] Such devices may be fabricated using conventional
techniques, known in the art, for example by casting a fluid
admixture of adhesive, active ingredients and vehicle onto the
backing layer, followed by lamination of the release liner.
Similarly, the adhesive mixture may be cast onto the release liner,
followed by lamination of the backing layer. Alternatively, the
active ingredients reservoir may be prepared in the absence of
active ingredients or excipient, and then loaded by "soaking" in an
active ingredients/vehicle mixture.
[0375] As with the topical formulations of the invention, the
active ingredients composition contained within the active
ingredients reservoirs of these laminated system may contain a
number of components. In some cases, the active ingredients may be
delivered "neat," i.e., in the absence of additional liquid. In
most cases, however, the active ingredients will be dissolved,
dispersed or suspended in a suitable pharmaceutically acceptable
vehicle, typically a solvent or gel. Other components, which may be
present, include preservatives, stabilizers, surfactants, and the
like.
[0376] It should be noted that the protein of the invention, such
as a high mannose lysosomal enzyme, is preferably administered to
the patient in need in an effective amount. As used herein,
"effective amount" means an amount necessary to achieve a selected
result. For example, an effective amount of the composition of the
invention may be selected for being useful for the treatment of a
lysosomal storage disease.
[0377] Pharmaceutical compositions suitable for use in context of
the present invention include compositions wherein the active
ingredients are contained in an amount effective to achieve the
intended purpose. More specifically, a therapeutically effective
amount means an amount of active ingredient effective to prevent,
alleviate or ameliorate symptoms of disease or prolong the survival
of the subject being treated.
[0378] Determination of a therapeutically effective amount is well
within the capability of those skilled in the art, especially in
light of the detailed disclosure provided herein.
[0379] For any active ingredient used in the methods of the
invention, the therapeutically effective amount or dose can be
estimated initially from activity assays in animals. For example, a
dose can be formulated in animal models to achieve a circulating
concentration range that includes the IC.sub.50 as determined by
activity assays.
[0380] Toxicity and therapeutic efficacy of the active ingredients
described herein can be determined by standard pharmaceutical
procedures in experimental animals, e.g., by determining the
IC.sub.50 and the LD.sub.50 (lethal dose causing death in 50% of
the tested animals) for a subject active ingredient. The data
obtained from these activity assays and animal studies can be used
in formulating a range of dosage for use in human. For example,
therapeutically effective doses suitable for treatment of genetic
disorders can be determined from the experiments with animal models
of these diseases.
[0381] The dosage may vary depending upon the dosage form employed
and the route of administration utilized. The exact formulation,
route of administration and dosage can be chosen by the individual
physician in view of the patient's condition. (See e.g., Fingl, et
al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.
1).
[0382] Dosage amount and interval may be adjusted individually to
provide plasma levels of the active moiety which are sufficient to
maintain the modulating effects, termed the minimal effective
concentration (MEC). The MEC will vary for each preparation, but
may optionally be estimated from whole animal data.
[0383] Dosage intervals can also be determined using the MEC value.
Preparations may optionally be administered using a regimen, which
maintains plasma levels above the MEC for 10-90% of the time,
preferable between 30-90% and most preferably 50-90%.
[0384] Depending on the severity and responsiveness of the
condition to be treated, dosing can also be a single administration
of a slow release composition described hereinabove, with course of
treatment lasting from several days to several weeks or until cure
is effected or diminution of the disease state is achieved.
[0385] Compositions of the present invention may, if desired, be
presented in a pack or dispenser device, such as an FDA approved
kit, which may contain one or more unit dosage forms containing the
active ingredient. The pack may, for example, comprise metal or
plastic foil, such as a blister pack. The pack or dispenser device
may be accompanied by instructions for administration. The pack or
dispenser may also be accompanied by a notice associated with the
container in a form prescribed by a governmental agency regulating
the manufacture, use or sale of pharmaceuticals, which notice is
reflective of approval by the agency of the form of the
compositions or human or veterinary administration. Such notice,
for example, may be of labeling approved by the U.S. Food and Drug
Administration for prescription drugs or of an approved product
insert. Compositions comprising an active ingredient of the
invention formulated in a compatible pharmaceutical carrier may
also be prepared, placed in an appropriate container, and labeled
for treatment of an indicated condition.
[0386] As used herein, the term "modulate" includes substantially
inhibiting, slowing or reversing the progression of a disease,
substantially ameliorating clinical symptoms of a disease or
condition, or substantially preventing the appearance of clinical
symptoms of a disease or condition. A "modulator" therefore
includes an agent which may modulate a disease or condition.
Other Embodiments
[0387] It is to be understood that while the invention has been
described in conjunction with the detailed description thereof, the
foregoing description is intended to illustrate and not limit the
scope of the invention, which is defined by the scope of the
appended claims. Other aspects, advantages, and modifications are
within the scope of the following claims.
REFERENCES
[0388] 1. Ma, J. K. C., Drake, P. M. W., and Christou, P. (2003)
Nature reviews 4, 794-805 [0389] 2. Lerouge, P., Cabanes-Macheteau,
M, Rayon, C, Fischette-Laine, A. C., Gomord, V, Faye, L. (1998)
Plant Mol Biol 38, 31-48 [0390] 3. Lee, R. E. (1982) Prog Clin Biol
Res 95, 177-217 [0391] 4. Grabowski, G. (1993) Adv Hum Genet. 21,
377-441 [0392] 5. Grabowski, G. A., and Hopkin, R. J. (2003) Annual
Review of Genomics and Human Genetics 4, 403-436 [0393] 6. Sorge,
J. W., C., Westwood, B., Beutler, E. (1985) Proc Natl Acad Sci USA.
82, 7289-7293 [0394] 7. Berg-Fussman, A., Grace, M., Ioannou, Y.,
and Grabowski, G. (1993) J. Biol. Chem. 268, 14861-14866 [0395] 8.
Grace, M., Grabowski, G A. (1990) Biochem Biophys Res Commun 168,
771-777 [0396] 9. Grace, M., Newman, K., Scheinker, V.,
Berg-Fussman, A., and Grabowski, G. (1994) J. Biol. Chem. 269,
2283-2291 [0397] 10. Barton, N. W., Brady, R. O., Dambrosia, J. M.,
Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J.,
Murray, G. J., Parker, R. I., Argoff, C. E., et al. (1991) N Engl J
Med. 324, 1464-1470 [0398] 11. Grabowski, G. A., Barton, N. W.,
Pastores, G., Dambrosia, J. M., Banerjee, T. K., McKee, M. A.,
Parker, C., Schiffmann, R., Hill, S. C., and Brady, R. O. (1995)
Ann Intern Med 122, 33-39 [0399] 12. Pastores, G. M., Sibille, A.
R., Grabowski, G. A. (1993) Blood 82, 408-416. [0400] 13. Weinreb,
N. J., Charrow, J, Andersson, H. C., Kaplan, P, Kolodny, E. H.,
Mistry, P, Pastores, G, Rosenbloom, B. E., Scott, C. R., Wappner,
R. S., Zimran, A. (2002) Am J Med 113, 112-119 [0401] 14.
Bijsterbosch, M. K., Donker, W, van de Bilt, H, van Weely, S, van
Berkel, T. J., Aerts, J M. (1996) Eur J Biochem 237, 344-349 [0402]
15. Friedman, B., Vaddi, K., Preston, C., Mahon, E., Cataldo, J.
R., and McPherson, J. M. (1999) Blood 93, 2807-2816 [0403] 16.
Furbish, F. S., Steer, C. J., Krett, N. L., Barranger, J. A. (1981)
Biochim Biophys Acta 673, 425-434 [0404] 17. Doebber, T., Wu, M.,
Bugianesi, R., Ponpipom, M., Furbish, F., Barranger, J., Brady, R.,
and Shen, T. (1982) J. Biol. Chem. 257, 2193-2199 [0405] 18. Dwek,
R. A., Butters, T. D., Platt, F. M., Zitzmann, N. (2002) Nature
reviews 1, 65-75 [0406] 19. Neuhaus, J. M., Rogers, J. C. (1998)
Plant Mol Biol 38, 127-144 [0407] 20. Vitale, A., and Galili, G.
(2001) Plant Physiol. 125, 115-118 [0408] 21. Hellens, R., Edwards,
E A., Leyland, N. R., Bean, S., Mullineaux, P. M. (2000) Plant Mol
Biol 42, 819-832 [0409] 22. Wurtele, E. S., Bulka, K. (1989) Plant
Sci 61, 253-262 [0410] 23. den Dulk-Ras, A., Hooykaas, P. J. (1995)
Methods Mol Biol. 55, 63-72 [0411] 24. Laemmli, U. K. (1970) Nature
reviews 227, 680-685 [0412] 25. Bradford, M. M. (1976) Anal Biochem
72, 248-254 [0413] 26. Stahl, P. G. S. (1982) J Cell Biol 93, 49-56
[0414] 27. Takasaki, S., Murray, G., Furbish, F., Brady, R.,
Barranger, J., and Kobata, A. (1984) J. Biol. Chem. 259,
10112-10117 [0415] 28. Lerouge, P., Cabanes-Macheteau, M., Rayon,
C., Fitchette-Laine, A. C., Gomord, V., and Faye, L. (1998) Plant
Mol. Biol. 38, 31-48 [0416] 29. Frigerio, L., Pastres, A., Prada,
A., and Vitale, A. (2001) Plant Cell 13, 1109-1126 [0417] 30.
Frigerio, L., de Virgilio, M., Prada, A., Faoro, F., and Vitale, A.
(1998) Plant Cell 10, 1031-1042 [0418] 31. Hadlington J L, D. J.
(2000) Curr Opin Plant Biol. 3, 461-468. [0419] 32. Okamoto, T.,
Shimada, T., Hara-Nishimura, I., Nishimura, M., and Minamikawa, T.
(2003) Plant Physiol. 132, 1892-1900 [0420] 33. Bardor, M.,
Faveeuw, C., Fitchette, A.-C., Gilbert, D., Galas, L., Trottein,
F., Faye, L., and Lerouge, P. (2003) Glycobiology 13, 427-434
Sequence CWU 1
1
15122PRTArtificial sequenceER signal peptide 1Met Lys Thr Asn Leu
Phe Leu Phe Leu Ile Phe Ser Leu Leu Leu Ser 1 5 10 15 Leu Ser Ser
Ala Glu Phe 20 27PRTArtificial sequenceVacuolar targeting signal
from Tobacco chitinase A 2Asp Leu Leu Val Asp Thr Met 1 5
321DNAArtificial sequenceSingle strand DNA oligonucleotide
3cagaattcgc ccgcccctgc a 21422DNAArtificial sequenceSingle strand
DNA oligonucleotide 4ctcagatctt ggcgatgcca ca 22519DNAArtificial
sequenceSingle strand DNA oligonucleotide 5ctcagaagac cagagggct
19617DNAArtificial sequenceSingle strand DNA oligonucleotide
6caaagcggcc atcgtgc 1771491DNAHomo sapiens 7gcccgcccct gcatccctaa
aagcttcggc tacagctcgg tggtgtgtgt ctgcaatgcc 60acatactgtg actcctttga
ccccccgacc tttcctgccc ttggtacctt cagccgctat 120gagagtacac
gcagtgggcg acggatggag ctgagtatgg ggcccatcca ggctaatcac
180acgggcacag gcctgctact gaccctgcag ccagaacaga agttccagaa
agtgaaggga 240tttggagggg ccatgacaga tgctgctgct ctcaacatcc
ttgccctgtc accccctgcc 300caaaatttgc tacttaaatc gtacttctct
gaagaaggaa tcggatataa catcatccgg 360gtacccatgg ccagctgtga
cttctccatc cgcacctaca cctatgcaga cacccctgat 420gatttccagt
tgcacaactt cagcctccca gaggaagata ccaagctcaa gatacccctg
480attcaccgag ccctgcagtt ggcccagcgt cccgtttcac tccttgccag
cccctggaca 540tcacccactt ggctcaagac caatggagcg gtgaatggga
aggggtcact caagggacag 600cccggagaca tctaccacca gacctgggcc
agatactttg tgaagttcct ggatgcctat 660gctgagcaca agttacagtt
ctgggcagtg acagctgaaa atgagccttc tgctgggctg 720ttgagtggat
accccttcca gtgcctgggc ttcacccctg aacatcagcg agacttcatt
780gcccgtgacc taggtcctac cctcgccaac agtactcacc acaatgtccg
cctactcatg 840ctggatgacc aacgcttgct gctgccccac tgggcaaagg
tggtactgac agacccagaa 900gcagctaaat atgttcatgg cattgctgta
cattggtacc tggactttct ggctccagcc 960aaagccaccc taggggagac
acaccgcctg ttccccaaca ccatgctctt tgcctcagag 1020gcctgtgtgg
gctccaagtt ctgggagcag agtgtgcggc taggctcctg ggatcgaggg
1080atgcagtaca gccacagcat catcacgaac ctcctgtacc atgtggtcgg
ctggaccgac 1140tggaaccttg ccctgaaccc cgaaggagga cccaattggg
tgcgtaactt tgtcgacagt 1200cccatcattg tagacatcac caaggacacg
ttttacaaac agcccatgtt ctaccacctt 1260ggccacttca gcaagttcat
tcctgagggc tcccagagag tggggctggt tgccagtcag 1320aagaacgacc
tggacgcagt ggcactgatg catcccgatg gctctgctgt tgtggtcgtg
1380ctaaaccgct cctctaagga tgtgcctctt accatcaagg atcctgctgt
gggcttcctg 1440gagacaatct cacctggcta ctccattcac acctacctgt
ggcatcgcca g 14918497PRTHomo sapiens 8Ala Arg Pro Cys Ile Pro Lys
Ser Phe Gly Tyr Ser Ser Val Val Cys 1 5 10 15 Val Cys Asn Ala Thr
Tyr Cys Asp Ser Phe Asp Pro Pro Thr Phe Pro 20 25 30 Ala Leu Gly
Thr Phe Ser Arg Tyr Glu Ser Thr Arg Ser Gly Arg Arg 35 40 45 Met
Glu Leu Ser Met Gly Pro Ile Gln Ala Asn His Thr Gly Thr Gly 50 55
60 Leu Leu Leu Thr Leu Gln Pro Glu Gln Lys Phe Gln Lys Val Lys Gly
65 70 75 80 Phe Gly Gly Ala Met Thr Asp Ala Ala Ala Leu Asn Ile Leu
Ala Leu 85 90 95 Ser Pro Pro Ala Gln Asn Leu Leu Leu Lys Ser Tyr
Phe Ser Glu Glu 100 105 110 Gly Ile Gly Tyr Asn Ile Ile Arg Val Pro
Met Ala Ser Cys Asp Phe 115 120 125 Ser Ile Arg Thr Tyr Thr Tyr Ala
Asp Thr Pro Asp Asp Phe Gln Leu 130 135 140 His Asn Phe Ser Leu Pro
Glu Glu Asp Thr Lys Leu Lys Ile Pro Leu 145 150 155 160 Ile His Arg
Ala Leu Gln Leu Ala Gln Arg Pro Val Ser Leu Leu Ala 165 170 175 Ser
Pro Trp Thr Ser Pro Thr Trp Leu Lys Thr Asn Gly Ala Val Asn 180 185
190 Gly Lys Gly Ser Leu Lys Gly Gln Pro Gly Asp Ile Tyr His Gln Thr
195 200 205 Trp Ala Arg Tyr Phe Val Lys Phe Leu Asp Ala Tyr Ala Glu
His Lys 210 215 220 Leu Gln Phe Trp Ala Val Thr Ala Glu Asn Glu Pro
Ser Ala Gly Leu 225 230 235 240 Leu Ser Gly Tyr Pro Phe Gln Cys Leu
Gly Phe Thr Pro Glu His Gln 245 250 255 Arg Asp Phe Ile Ala Arg Asp
Leu Gly Pro Thr Leu Ala Asn Ser Thr 260 265 270 His His Asn Val Arg
Leu Leu Met Leu Asp Asp Gln Arg Leu Leu Leu 275 280 285 Pro His Trp
Ala Lys Val Val Leu Thr Asp Pro Glu Ala Ala Lys Tyr 290 295 300 Val
His Gly Ile Ala Val His Trp Tyr Leu Asp Phe Leu Ala Pro Ala 305 310
315 320 Lys Ala Thr Leu Gly Glu Thr His Arg Leu Phe Pro Asn Thr Met
Leu 325 330 335 Phe Ala Ser Glu Ala Cys Val Gly Ser Lys Phe Trp Glu
Gln Ser Val 340 345 350 Arg Leu Gly Ser Trp Asp Arg Gly Met Gln Tyr
Ser His Ser Ile Ile 355 360 365 Thr Asn Leu Leu Tyr His Val Val Gly
Trp Thr Asp Trp Asn Leu Ala 370 375 380 Leu Asn Pro Glu Gly Gly Pro
Asn Trp Val Arg Asn Phe Val Asp Ser 385 390 395 400 Pro Ile Ile Val
Asp Ile Thr Lys Asp Thr Phe Tyr Lys Gln Pro Met 405 410 415 Phe Tyr
His Leu Gly His Phe Ser Lys Phe Ile Pro Glu Gly Ser Gln 420 425 430
Arg Val Gly Leu Val Ala Ser Gln Lys Asn Asp Leu Asp Ala Val Ala 435
440 445 Leu Met His Pro Asp Gly Ser Ala Val Val Val Val Leu Asn Arg
Ser 450 455 460 Ser Lys Asp Val Pro Leu Thr Ile Lys Asp Pro Ala Val
Gly Phe Leu 465 470 475 480 Glu Thr Ile Ser Pro Gly Tyr Ser Ile His
Thr Tyr Leu Trp His Arg 485 490 495 Gln 9338DNACauliflower mosaic
virus 9ttttcacaaa gggtaatatc gggaaacctc ctcggattcc attgcccagc
tatctgtcac 60ttcatcgaaa ggacagtaga aaaggaaggt ggctcctaca aatgccatca
ttgcgataaa 120ggaaaggcta tcgttcaaga tgcctctacc gacagtggtc
ccaaagatgg acccccaccc 180acgaggaaca tcgtggaaaa agaagacgtt
ccaaccacgt cttcaaagca agtggattga 240tgtgatatct ccactgacgt
aagggatgac gcacaatccc actatccttc gcaagaccct 300tcctctatat
aaggaagttc atttcatttg gagaggac 3381066DNAArtificial sequenceNucleic
acid sequence encoding the ER signal peptide 10atgaagacta
atctttttct ctttctcatc ttttcacttc tcctatcatt atcctcggcc 60gaattc
661121DNAArtificial sequenceNucleic acid sequence encoding the
vacuolar targeting sequence 11gatcttttag tcgatactat g
2112167DNAArtificial sequenceNucleic acid sequence of the
Agrobacterium tumefaciens terminator 12taatttcatg atctgttttg
ttgtattccc ttgcaatgca gggcctaggg ctatgaataa 60agttaatgtg tgaatgtgtg
aatgtgtgat tgtgacctga agggatcacg actataatcg 120tttataataa
acaaagactt tgtcccaaaa accccccccc cngcaga 167132186DNAArtificial
sequencenucleic acid sequence encoding high mannose human
glucocerebrosidase (GCD) 13ttttcacaaa gggtaatatc gggaaacctc
ctcggattcc attgcccagc tatctgtcac 60ttcatcgaaa ggacagtaga aaaggaaggt
ggctcctaca aatgccatca ttgcgataaa 120ggaaaggcta tcgttcaaga
tgcctctacc gacagtggtc ccaaagatgg acccccaccc 180acgaggaaca
tcgtggaaaa agaagacgtt ccaaccacgt cttcaaagca agtggattga
240tgtgatatct ccactgacgt aagggatgac gcacaatccc actatccttc
gcaagaccct 300tcctctatat aaggaagttc atttcatttg gagaggacag
gcttcttgag atccttcaac 360aattaccaac aacaacaaac aacaaacaac
attacaatta ctatttacaa ttacagtcga 420gggatccaag gagatataac
aatgaagact aatctttttc tctttctcat cttttcactt 480ctcctatcat
tatcctcggc cgaattcgcc cgcccctgca tccctaaaag cttcggctac
540agctcggtgg tgtgtgtctg caatgccaca tactgtgact cctttgaccc
cccgaccttt 600cctgcccttg gtaccttcag ccgctatgag agtacacgca
gtgggcgacg gatggagctg 660agtatggggc ccatccaggc taatcacacg
ggcacaggcc tgctactgac cctgcagcca 720gaacagaagt tccagaaagt
gaagggattt ggaggggcca tgacagatgc tgctgctctc 780aacatccttg
ccctgtcacc ccctgcccaa aatttgctac ttaaatcgta cttctctgaa
840gaaggaatcg gatataacat catccgggta cccatggcca gctgtgactt
ctccatccgc 900acctacacct atgcagacac ccctgatgat ttccagttgc
acaacttcag cctcccagag 960gaagatacca agctcaagat acccctgatt
caccgagccc tgcagttggc ccagcgtccc 1020gtttcactcc ttgccagccc
ctggacatca cccacttggc tcaagaccaa tggagcggtg 1080aatgggaagg
ggtcactcaa gggacagccc ggagacatct accaccagac ctgggccaga
1140tactttgtga agttcctgga tgcctatgct gagcacaagt tacagttctg
ggcagtgaca 1200gctgaaaatg agccttctgc tgggctgttg agtggatacc
ccttccagtg cctgggcttc 1260acccctgaac atcagcgaga cttcattgcc
cgtgacctag gtcctaccct cgccaacagt 1320actcaccaca atgtccgcct
actcatgctg gatgaccaac gcttgctgct gccccactgg 1380gcaaaggtgg
tactgacaga cccagaagca gctaaatatg ttcatggcat tgctgtacat
1440tggtacctgg actttctggc tccagccaaa gccaccctag gggagacaca
ccgcctgttc 1500cccaacacca tgctctttgc ctcagaggcc tgtgtgggct
ccaagttctg ggagcagagt 1560gtgcggctag gctcctggga tcgagggatg
cagtacagcc acagcatcat cacgaacctc 1620ctgtaccatg tggtcggctg
gaccgactgg aaccttgccc tgaaccccga aggaggaccc 1680aattgggtgc
gtaactttgt cgacagtccc atcattgtag acatcaccaa ggacacgttt
1740tacaaacagc ccatgttcta ccaccttggc cacttcagca agttcattcc
tgagggctcc 1800cagagagtgg ggctggttgc cagtcagaag aacgacctgg
acgcagtggc actgatgcat 1860cccgatggct ctgctgttgt ggtcgtgcta
aaccgctcct ctaaggatgt gcctcttacc 1920atcaaggatc ctgctgtggg
cttcctggag acaatctcac ctggctactc cattcacacc 1980tacctgtggc
atcgccaaga tcttttagtc gatactatgt aatttcatga tctgttttgt
2040tgtattccct tgcaatgcag ggcctagggc tatgaataaa gttaatgtgt
gaatgtgtga 2100atgtgtgatt gtgacctgaa gggatcacga ctataatcgt
ttataataaa caaagacttt 2160gtcccaaaaa cccccccccc ngcaga
218614526PRTArtificial sequenceHigh mannose human
glucocerebrosidase (GCD) 14Met Lys Thr Asn Leu Phe Leu Phe Leu Ile
Phe Ser Leu Leu Leu Ser 1 5 10 15 Leu Ser Ser Ala Glu Phe Ala Arg
Pro Cys Ile Pro Lys Ser Phe Gly 20 25 30 Tyr Ser Ser Val Val Cys
Val Cys Asn Ala Thr Tyr Cys Asp Ser Phe 35 40 45 Asp Pro Pro Thr
Phe Pro Ala Leu Gly Thr Phe Ser Arg Tyr Glu Ser 50 55 60 Thr Arg
Ser Gly Arg Arg Met Glu Leu Ser Met Gly Pro Ile Gln Ala 65 70 75 80
Asn His Thr Gly Thr Gly Leu Leu Leu Thr Leu Gln Pro Glu Gln Lys 85
90 95 Phe Gln Lys Val Lys Gly Phe Gly Gly Ala Met Thr Asp Ala Ala
Ala 100 105 110 Leu Asn Ile Leu Ala Leu Ser Pro Pro Ala Gln Asn Leu
Leu Leu Lys 115 120 125 Ser Tyr Phe Ser Glu Glu Gly Ile Gly Tyr Asn
Ile Ile Arg Val Pro 130 135 140 Met Ala Ser Cys Asp Phe Ser Ile Arg
Thr Tyr Thr Tyr Ala Asp Thr 145 150 155 160 Pro Asp Asp Phe Gln Leu
His Asn Phe Ser Leu Pro Glu Glu Asp Thr 165 170 175 Lys Leu Lys Ile
Pro Leu Ile His Arg Ala Leu Gln Leu Ala Gln Arg 180 185 190 Pro Val
Ser Leu Leu Ala Ser Pro Trp Thr Ser Pro Thr Trp Leu Lys 195 200 205
Thr Asn Gly Ala Val Asn Gly Lys Gly Ser Leu Lys Gly Gln Pro Gly 210
215 220 Asp Ile Tyr His Gln Thr Trp Ala Arg Tyr Phe Val Lys Phe Leu
Asp 225 230 235 240 Ala Tyr Ala Glu His Lys Leu Gln Phe Trp Ala Val
Thr Ala Glu Asn 245 250 255 Glu Pro Ser Ala Gly Leu Leu Ser Gly Tyr
Pro Phe Gln Cys Leu Gly 260 265 270 Phe Thr Pro Glu His Gln Arg Asp
Phe Ile Ala Arg Asp Leu Gly Pro 275 280 285 Thr Leu Ala Asn Ser Thr
His His Asn Val Arg Leu Leu Met Leu Asp 290 295 300 Asp Gln Arg Leu
Leu Leu Pro His Trp Ala Lys Val Val Leu Thr Asp 305 310 315 320 Pro
Glu Ala Ala Lys Tyr Val His Gly Ile Ala Val His Trp Tyr Leu 325 330
335 Asp Phe Leu Ala Pro Ala Lys Ala Thr Leu Gly Glu Thr His Arg Leu
340 345 350 Phe Pro Asn Thr Met Leu Phe Ala Ser Glu Ala Cys Val Gly
Ser Lys 355 360 365 Phe Trp Glu Gln Ser Val Arg Leu Gly Ser Trp Asp
Arg Gly Met Gln 370 375 380 Tyr Ser His Ser Ile Ile Thr Asn Leu Leu
Tyr His Val Val Gly Trp 385 390 395 400 Thr Asp Trp Asn Leu Ala Leu
Asn Pro Glu Gly Gly Pro Asn Trp Val 405 410 415 Arg Asn Phe Val Asp
Ser Pro Ile Ile Val Asp Ile Thr Lys Asp Thr 420 425 430 Phe Tyr Lys
Gln Pro Met Phe Tyr His Leu Gly His Phe Ser Lys Phe 435 440 445 Ile
Pro Glu Gly Ser Gln Arg Val Gly Leu Val Ala Ser Gln Lys Asn 450 455
460 Asp Leu Asp Ala Val Ala Leu Met His Pro Asp Gly Ser Ala Val Val
465 470 475 480 Val Val Leu Asn Arg Ser Ser Lys Asp Val Pro Leu Thr
Ile Lys Asp 485 490 495 Pro Ala Val Gly Phe Leu Glu Thr Ile Ser Pro
Gly Tyr Ser Ile His 500 505 510 Thr Tyr Leu Trp His Arg Gln Asp Leu
Leu Val Asp Thr Met 515 520 525 15506PRTArtificial
sequenceProcessed plant produced human recombinant GCD protein
15Glu Phe Ala Arg Pro Cys Ile Pro Lys Ser Phe Gly Tyr Ser Ser Val 1
5 10 15 Val Cys Val Cys Asn Ala Thr Tyr Cys Asp Ser Phe Asp Pro Pro
Thr 20 25 30 Phe Pro Ala Leu Gly Thr Phe Ser Arg Tyr Glu Ser Thr
Arg Ser Gly 35 40 45 Arg Arg Met Glu Leu Ser Met Gly Pro Ile Gln
Ala Asn His Thr Gly 50 55 60 Thr Gly Leu Leu Leu Thr Leu Gln Pro
Glu Gln Lys Phe Gln Lys Val 65 70 75 80 Lys Gly Phe Gly Gly Ala Met
Thr Asp Ala Ala Ala Leu Asn Ile Leu 85 90 95 Ala Leu Ser Pro Pro
Ala Gln Asn Leu Leu Leu Lys Ser Tyr Phe Ser 100 105 110 Glu Glu Gly
Ile Gly Tyr Asn Ile Ile Arg Val Pro Met Ala Ser Cys 115 120 125 Asp
Phe Ser Ile Arg Thr Tyr Thr Tyr Ala Asp Thr Pro Asp Asp Phe 130 135
140 Gln Leu His Asn Phe Ser Leu Pro Glu Glu Asp Thr Lys Leu Lys Ile
145 150 155 160 Pro Leu Ile His Arg Ala Leu Gln Leu Ala Gln Arg Pro
Val Ser Leu 165 170 175 Leu Ala Ser Pro Trp Thr Ser Pro Thr Trp Leu
Lys Thr Asn Gly Ala 180 185 190 Val Asn Gly Lys Gly Ser Leu Lys Gly
Gln Pro Gly Asp Ile Tyr His 195 200 205 Gln Thr Trp Ala Arg Tyr Phe
Val Lys Phe Leu Asp Ala Tyr Ala Glu 210 215 220 His Lys Leu Gln Phe
Trp Ala Val Thr Ala Glu Asn Glu Pro Ser Ala 225 230 235 240 Gly Leu
Leu Ser Gly Tyr Pro Phe Gln Cys Leu Gly Phe Thr Pro Glu 245 250 255
His Gln Arg Asp Phe Ile Ala Arg Asp Leu Gly Pro Thr Leu Ala Asn 260
265 270 Ser Thr His His Asn Val Arg Leu Leu Met Leu Asp Asp Gln Arg
Leu 275 280 285 Leu Leu Pro His Trp Ala Lys Val Val Leu Thr Asp Pro
Glu Ala Ala 290 295 300 Lys Tyr Val His Gly Ile Ala Val His Trp Tyr
Leu Asp Phe Leu Ala 305 310 315 320 Pro Ala Lys Ala Thr Leu Gly Glu
Thr His Arg Leu Phe Pro Asn Thr 325 330 335 Met Leu Phe Ala Ser Glu
Ala Cys Val Gly Ser Lys Phe Trp Glu Gln 340 345 350 Ser Val Arg Leu
Gly Ser Trp Asp Arg Gly Met Gln Tyr Ser His Ser 355 360 365 Ile Ile
Thr Asn Leu Leu Tyr His Val Val Gly Trp Thr Asp Trp Asn 370 375 380
Leu Ala Leu Asn Pro Glu Gly Gly Pro Asn Trp Val Arg Asn Phe Val 385
390 395 400 Asp Ser Pro Ile
Ile Val Asp Ile Thr Lys Asp Thr Phe Tyr Lys Gln 405 410 415 Pro Met
Phe Tyr His Leu Gly His Phe Ser Lys Phe Ile Pro Glu Gly 420 425 430
Ser Gln Arg Val Gly Leu Val Ala Ser Gln Lys Asn Asp Leu Asp Ala 435
440 445 Val Ala Leu Met His Pro Asp Gly Ser Ala Val Val Val Val Leu
Asn 450 455 460 Arg Ser Ser Lys Asp Val Pro Leu Thr Ile Lys Asp Pro
Ala Val Gly 465 470 475 480 Phe Leu Glu Thr Ile Ser Pro Gly Tyr Ser
Ile His Thr Tyr Leu Trp 485 490 495 His Arg Gln Asp Leu Leu Val Asp
Thr Met 500 505
* * * * *